<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Breast Cancer</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Breast Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">3134</journal-id><journal-id journal-id-type="pmc-domain">npjbcancer</journal-id><journal-title-group><journal-title>NPJ Breast Cancer</journal-title></journal-title-group><issn pub-type="epub">2374-4677</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11377442</article-id><article-id pub-id-type="pmcid-ver">PMC11377442.1</article-id><article-id pub-id-type="pmcaid">11377442</article-id><article-id pub-id-type="pmcaiid">11377442</article-id><article-id pub-id-type="pmid">39237557</article-id><article-id pub-id-type="doi">10.1038/s41523-024-00686-8</article-id><article-id pub-id-type="publisher-id">686</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>BRCA genetic testing and counseling in breast cancer: how do we meet our patients&#8217; needs?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9566-0209</contrib-id><name name-style="western"><surname>Dubsky</surname><given-names initials="P">Peter</given-names></name><address><email>peter.dubsky@hirslanden.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8537-3743</contrib-id><name name-style="western"><surname>Jackisch</surname><given-names initials="C">Christian</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Im</surname><given-names initials="SA">Seock-Ah</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9156-8723</contrib-id><name name-style="western"><surname>Hunt</surname><given-names initials="KK">Kelly K.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="CF">Chien-Feng</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Unger</surname><given-names initials="S">Sheila</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paluch-Shimon</surname><given-names initials="S">Shani</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02ss4n480</institution-id><institution-id institution-id-type="GRID">grid.512769.e</institution-id><institution>Breast and Tumor Center, </institution><institution>Hirslanden Klinik St. Anna, </institution></institution-wrap>Lucerne, Switzerland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00kgrkn83</institution-id><institution-id institution-id-type="GRID">grid.449852.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 1456 7938</institution-id><institution>University of Lucerne, </institution><institution>Faculty of Health Sciences and Medicine, </institution></institution-wrap>Lucerne, Switzerland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04k4vsv28</institution-id><institution-id institution-id-type="GRID">grid.419837.0</institution-id><institution>Department of Obstetrics and Gynecology, Breast and Gynecologic Cancer Center, </institution><institution>Sana Klinikum Offenbach, </institution></institution-wrap>Offenbach, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, </institution><institution>Seoul National University, </institution></institution-wrap>Seoul, Republic of Korea </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02r6fpx29</institution-id><institution-id institution-id-type="GRID">grid.59784.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0622 9172</institution-id><institution>National Institute of Cancer Research, </institution><institution>National Health Research Institutes, </institution></institution-wrap>Tainan, Taiwan </aff><aff id="Aff7"><label>7</label>Genetica, Lausanne, Switzerland </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qxff017</institution-id><institution-id institution-id-type="GRID">grid.9619.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0538</institution-id><institution>Hadassah University Hospital &amp; Faculty of Medicine, </institution><institution>Hebrew University, </institution></institution-wrap>Jerusalem, Israel </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">452202</issue-id><elocation-id>77</elocation-id><history><date date-type="received"><day>26</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>06</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-07 00:25:14.363"><day>07</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41523_2024_Article_686.pdf"/><abstract id="Abs1"><p id="Par1"><italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> are tumor suppressor genes that have been linked to inherited susceptibility of breast cancer. Germline <italic toggle="yes">BRCA1/2</italic> pathogenic or likely pathogenic variants (gBRCAm) are clinically relevant for treatment selection in breast cancer because they confer sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. <italic toggle="yes">BRCA1/2</italic> mutation status may also impact decisions on other systemic therapies, risk-reducing measures, and choice of surgery. Consequently, demand for gBRCAm testing has increased. Several barriers to genetic testing exist, including limited access to testing facilities, trained counselors, and psychosocial support, as well as the financial burden of testing. Here, we describe current implications of gBRCAm testing for patients with breast cancer, summarize current approaches to gBRCAm testing, provide potential solutions to support wider adoption of mainstreaming testing practices, and consider future directions of testing.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Breast cancer</kwd><kwd>Breast cancer</kwd><kwd>Genetic testing</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100004325</institution-id><institution>AstraZeneca</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100004334</institution-id><institution>Merck (Merck &amp; Co., Inc.)</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Merck (Merck &amp; Co., Inc.)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Merck (Merck &amp; Co., Inc.)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Merck (Merck &amp; Co., Inc.)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Merck (Merck &amp; Co., Inc.)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Merck (Merck &amp; Co., Inc.)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Merck (Merck &amp; Co., Inc.)</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2"><italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> were identified in the 1990s as genes linked to inherited susceptibility to breast cancer<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. As tumor suppressor genes, they encode proteins that are crucial for the repair of complex DNA damage (such as double-strand breaks) by homologous recombination<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Germline mutations (i.e., pathogenic or likely pathogenic variants) in <italic toggle="yes">BRCA1/2</italic> (gBRCAm) affecting this vital DNA repair pathway predispose individuals to developing breast cancer by impairing homologous recombination and causing genomic instability<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par3">The advent of poly(ADP-ribose) polymerase (PARP) inhibitors has revolutionized the therapeutic landscape for cancers associated with gBRCAm, including breast, ovarian, prostate, and pancreatic cancer<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. For breast cancer, the focus of this article, PARP inhibitors are approved for early and advanced disease harboring gBRCAm based on the results of major clinical trials: for olaparib, OlympiAD and OlympiA; and for talazoparib, EMBRACA<sup><xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref></sup>. Given the opportunity for therapeutic targeting of gBRCAm, timely determination of gBRCAm status is critical to guide treatment decisions, and demand for gBRCAm testing has rapidly increased in recent years<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. High-throughput sequencing technologies have made analysis of cancer-susceptibility genes rapid and affordable<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. However, there is concern that the demand for gBRCAm testing may overwhelm current genetic services<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Furthermore, barriers at the individual-, provider-, systems-, and policy-levels exist, which restrict access to genetic testing resources and genetic counseling<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Innovative methods of mainstreaming genetic services may help overcome some of these challenges. Education and resources to support appropriate counseling for gBRCAm testing, as well as information on the implications of testing, and models for genetic test consent, are urgently needed to support the evolving clinical space.</p><p id="Par4">In this review, we describe the implications of gBRCAm testing for potential surgical approaches and treatment in patients with breast cancer, summarize the various approaches to gBRCAm testing (including traditional and alternative models), provide practical resources to support mainstreaming of the gBRCAm testing pathway, and consider the relevance of genetic testing in breast cancer in the future.</p></sec><sec id="Sec2"><title>Biology of BRCAm in breast cancer</title><p id="Par5">Hereditary breast and ovarian cancer (HBOC) syndrome accounts for approximately 10% of breast cancer cases<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> are the main genes involved in genetic susceptibility to breast cancer<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. HBOC is associated with early-onset breast cancer, and an increased risk of other cancers, including ovarian, pancreatic, fallopian tube, and prostate<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. The cumulative lifetime risk of developing breast cancer by age 80 years is high at 72 and 69% for <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> mutation carriers, respectively<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Female gBRCAm carriers also have a 44% (<italic toggle="yes">BRCA1</italic>) and 17% (<italic toggle="yes">BRCA2</italic>) cumulative risk of developing ovarian cancer<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par6">Patients harboring gBRCAm are more likely to develop breast cancer at a younger age, with approximately 12% of the cases arising in women &#8804;40&#8201;years of age attributed to pathogenic or likely pathogenic variants in <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic><sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. These breast cancers have distinct biological features: among individuals with g<italic toggle="yes">BRCA1</italic>m, breast cancers are typically hormone receptor-negative (~76%) and human epidermal growth factor receptor 2 (HER2)-negative (94%), while breast cancers developing in individuals with g<italic toggle="yes">BRCA2</italic>m are more frequently hormone receptor-positive (83%) and HER2-negative (89%)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p></sec><sec id="Sec3"><title>Goals of gBRCAm testing in breast cancer</title><p id="Par7">Available evidence regarding surgical and systemic treatment outcomes in patients with gBRCAm breast cancer highlights the importance of determining gBRCAm status prior to finalizing treatment decisions. Clinical practice guidelines further reinforce the role of gBRCAm testing in the context of treatment decision-making, beyond its importance for risk management and cascade testing<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. The presence of gBRCAm may impact decisions about risk-reducing measures, choice of surgery, and systemic therapies (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The pathway from gBRCAm testing to decisions relating to risk-reducing measures, choice of surgery, and systemic therapies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e425" position="float" orientation="portrait" xlink:href="41523_2024_686_Fig1_HTML.jpg"/></fig></p><sec id="Sec4"><title>Surgical decision-making</title><sec id="Sec5"><title>Breast-conserving surgery (BCS)</title><p id="Par8">BCS aims to remove the breast tumor, with clear margins, in a manner that is cosmetically acceptable to the patient<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Although BCS is recommended for most patients with early-stage operable breast cancer<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, the best approach for patients harboring gBRCAm is unclear. Practice guidelines recommend that gBRCAm status should not preclude the use of BCS as a surgical option for breast cancer<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. However, these patients should be counseled regarding the risk of ipsilateral breast cancer recurrence, new primary breast cancer in the treated breast, and contralateral breast cancer, noting that intensified surveillance is a reasonable treatment strategy for breast cancer<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>.</p></sec><sec id="Sec6"><title>Contralateral risk-reducing mastectomy (CRRM)</title><p id="Par9">Some women with a confirmed gBRCAm opt for CRRM over BCS, which is removal of the unaffected breast to reduce the risk of contralateral breast cancer, with or without the option of breast reconstruction<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. A meta-analysis of outcomes in patients with gBRCAm found that CRRM reduced the relative risk of contralateral breast cancer by 93% versus surveillance and significantly increased overall survival (OS) versus surveillance<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. It should be noted that benefit from CRRM was not maintained in all studies after adjusting for confounding factors<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, and the absolute survival benefits of mastectomy (both ipsilateral and contralateral) are heavily dependent on patient prognosis; patients with aggressive types of disease, and especially those with little response from neoadjuvant systemic therapy regimens, are at higher risk from distant metastasis than local recurrence or a new primary in the contralateral breast.</p></sec><sec id="Sec7"><title>Risk-reducing salpingo-oophorectomy (RRSO)</title><p id="Par10">While RRSO is indicated in gBRCAm carriers, its effect on breast cancer risk reduction is not clear<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. A recent systematic review and meta-analysis of 21,022 patients demonstrated a 37 and 49% reduction in the risk of developing breast cancer following RRSO compared with no RRSO in patients with g<italic toggle="yes">BRCA1</italic>m and g<italic toggle="yes">BRCA2</italic>m, respectively, with the effect particularly pronounced in younger women with gBRCAm<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. A retrospective analysis in 676 women harboring gBRCAm showed that oophorectomy decreased mortality in patients with g<italic toggle="yes">BRCA1</italic>m and decreased breast cancer-specific mortality in patients with estrogen receptor (ER)-negative gBRCAm breast cancer<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Other studies have failed to demonstrate a benefit of RRSO on breast cancer risk<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>.</p></sec></sec><sec id="Sec8"><title>Systemic treatment decision-making</title><sec id="Sec9"><title>Chemotherapy</title><p id="Par11">gBRCAm advanced breast cancers are sensitive to platinum-based and non-platinum-based chemotherapy regimens<sup><xref ref-type="bibr" rid="CR26">26</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref></sup>. For early breast cancer, patients with gBRCAm are treated with anthracycline/taxane-based regimens, similar to those individuals with sporadic breast cancers<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. The clinical value of adding platinum therapy to neoadjuvant chemotherapy for patients with gBRCAm tumors is inconclusive. The phase 3 BrighTNess trial concluded that the addition of carboplatin, with or without veliparib, to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates among patients with triple-negative breast cancer (TNBC), regardless of gBRCA status<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Furthermore, a meta-analysis of neoadjuvant regimens in patients with gBRCAm TNBC reported improved pCR rates when platin derivatives were combined with anthracyclines and taxanes, although it was unclear if this combination offered a clinically meaningful benefit over standard chemotherapy alone<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. However, GeparSixto and INFORM did not show a benefit to adding carboplatin or cisplatin, respectively, to neoadjuvant chemotherapy for patients with gBRCAm early breast cancer<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. Exploratory translational analyses of BrighTNess sought to elucidate the differences in benefit observed for patients with breast cancer and gBRCAm<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Higher PAM50 proliferation score, CIN70 score, and GeparSixto immune signature were associated with higher odds of pCR for both patients with and without gBRCAm, and thus have been proposed as potentially useful biomarkers for determining addition of carboplatin to neoadjuvant chemotherapy<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, but have yet to be validated for clinical practice.</p></sec><sec id="Sec10"><title>PARP inhibition</title><p id="Par12">PARP inhibitors block the enzyme that has a vital role in repairing DNA single-strand breaks. They exploit the double-strand break repair deficiency of BRCAm cells, which accumulate unrepaired, toxic DNA double-strand breaks, thus resulting in tumor cell death (i.e., synthetic lethality). Olaparib is licensed for the adjuvant treatment of gBRCAm, HER2-negative high-risk early breast cancer, and for gBRCAm (tumor BRCAm in Japan), HER2-negative locally advanced (EU) or metastatic (EU and US) breast cancer. Talazoparib is approved for the treatment of gBRCAm, HER2-negative locally advanced or metastatic breast cancer in the US, Europe, and several other countries worldwide.</p><p id="Par13">For advanced gBRCAm HER2-negative breast cancer, PARP inhibitors were approved based on the results of the OlympiAD (olaparib) and EMBRACA (talazoparib) clinical trials<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. In OlympiAD, olaparib had significantly improved median progression-free survival (PFS) versus standard chemotherapy treatment of physician&#8217;s choice (7.0 months vs 4.2 months; HR 0.58 [95% CI 0.43&#8211;0.80]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) in patients with gBRCAm HER2-negative metastatic breast cancer<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Median OS was 19.3 months for olaparib and 17.1 months for standard chemotherapy (HR 0.89 [95% CI 0.67&#8211;1.18])<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. In subanalyses, a potential OS benefit with first-line olaparib versus chemotherapy was observed (median 22.6 vs 14.7 months; HR 0.55 [95% CI 0.33&#8211;0.95]), with 3-year survival at 40.8% with olaparib and 12.8% with treatment of physician&#8217;s choice, which, notably, did not include a platinum regimen<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. In EMBRACA, talazoparib significantly improved median PFS versus standard chemotherapy (8.6 vs 5.6 months; HR 0.54 [95% CI 0.41&#8211;0.71]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) in patients with gBRCAm advanced breast cancer<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, with no observed improvements in OS<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p><p id="Par14">For early breast cancer, olaparib was approved based on the results of the phase 3 OlympiA study in patients with high-risk early gBRCAm HER2-negative breast cancer who had completed local treatment and neoadjuvant or adjuvant chemotherapy<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. In the second prespecified analysis of OlympiA, adjuvant olaparib was associated with significantly improved OS versus placebo, with a 32% reduced risk of death (HR 0.68; 98.5% CI 0.47&#8211;0.97; <italic toggle="yes">P</italic>&#8201;=&#8201;0.009)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Significantly improved invasive disease-free survival (IDFS; HR 0.63; 95% CI 0.50&#8211;0.78) was also shown, consistent with the significantly improved IDFS reported at the first prespecified analysis (HR 0.58; 99.5% CI 0.41&#8211;0.82; <italic toggle="yes">P</italic>&#8201;=&#8201;0.001)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par15">These positive results in the adjuvant setting raised the question of whether PARP inhibitors may also have a place for neoadjuvant treatment of HER2-negative early breast cancer; however, trials have reported mixed results. In the BrighTNess trial, described above, addition of veliparib did not add benefit over neoadjuvant carboplatin/paclitaxel alone<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. The phase 2 GeparOLA study comparing neoadjuvant paclitaxel plus olaparib to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombinant deficiency did not meet its primary endpoint (exclusion of a pCR rate of &#8804;55%)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>, but did report a numerically improved pCR rate with paclitaxel/olaparib followed by epirubicin/cyclophosphamide (55.1%) versus paclitaxel/carboplatinum (48.6%) followed by epirubicin/cyclophosphamide, and a more favorable tolerability profile for paclitaxel/olaparib<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. In the single-arm neoTALA trial, patients with gBRCAm, early-stage TNBC were treated with talazoparib followed by definitive surgery<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Although neoadjuvant talazoparib was active, the pCR rates did not meet the prespecified threshold of efficacy<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Other neoadjuvant trials are ongoing to enhance our understanding of the potential use of PARP inhibitors in early breast cancer. Of potential interest is the opportunity to evaluate alternative PARP inhibitor combinations (e.g., with immunotherapy), and tailor therapy according to the patient. For example, in the ongoing OlympiaN trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05498155">NCT05498155</ext-link>) patients with deleterious/suspected deleterious BRCAm and operable, early-stage, HER2-negative, ER-negative/ER-low breast cancer are assigned olaparib (lower-risk cohort) or olaparib plus durvalumab (higher-risk cohort), and assessed for pCR<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>.</p><p id="Par16">PARP inhibitors are an important treatment strategy for gBRCAm breast cancer and rely on timely access to genetic testing to guide the most appropriate treatment selection, particularly in the early breast cancer setting.</p></sec><sec id="Sec11"><title>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors</title><p id="Par17">A CDK4/6 inhibitor in combination with endocrine therapy is a recommended option for first-line treatment for certain patients with hormone receptor-positive/HER2-negative advanced or metastatic breast cancer<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. Use of CDK4/6 inhibitors has also extended into earlier lines of treatment, with abemaciclib plus endocrine therapy a treatment option in the adjuvant setting for patients with hormone receptor-positive/HER2-negative, high-risk breast cancer<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, and positive results having been reported for ribociclib (NATALEE)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. While the optimal sequence is not known, recent guideline updates note that when patients are eligible for both adjuvant olaparib and abemaciclib then olaparib should be given first<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. Real-world evidence has suggested that patients with hormone receptor-positive advanced breast cancer and gBRCAm may have inferior outcomes with CDK4/6 inhibition or endocrine therapy versus those without gBRCAm<sup><xref ref-type="bibr" rid="CR45">45</xref>&#8211;<xref ref-type="bibr" rid="CR49">49</xref></sup>. This emerging finding highlights the potential importance of early detection of gBRCAm in patients with hormone receptor-positive breast cancer ahead of treatment selection, especially in light of recent CDK4/6 inhibitor approval in the early breast cancer setting.</p></sec><sec id="Sec12"><title>Immunotherapy</title><p id="Par18">There is limited evidence on the effectiveness of immunotherapy in patients with gBRCAm breast cancer. A recent substudy from the phase 3 IMpassion130 trial of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab showed that, in combination with nab-paclitaxel, patients with PD-L1-positive advanced TNBC had an OS and PFS benefit regardless of <italic toggle="yes">BRCA1/2</italic> mutation status (germline or somatic)<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. The efficacy of neoadjuvant PARP inhibition in combination with immunotherapy is under investigation; for example, olaparib in combination with durvalumab is being investigated in the aforementioned OlympiaN study<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>.</p></sec></sec><sec id="Sec13"><title>Screening and counseling for family members</title><p id="Par19">The burden of gBRCAm in breast cancer extends beyond the affected individual, with other family members facing decisions regarding gBRCAm testing, as well as considerations of family planning. In case of a familial association, genetic testing is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>&#174;</sup>) for unaffected family members<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. If a pre-symptomatic individual is identified as a carrier of gBRCAm, intensified surveillance for breast cancer is recommended, which differs per guideline but may include regular magnetic resonance imaging (MRI), ultrasound, mammography, and/or clinical breast exam, with guidance provided based on age<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. For patients harboring gBRCAm with a diagnosis of breast cancer who have not undergone bilateral mastectomy, National Comprehensive Cancer Network<sup>&#174;</sup> (NCCN<sup>&#174;</sup>) recommends that breast MRI and mammography should continue as recommended, based on age<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>.</p><p id="Par20">For individuals undergoing pre-symptomatic testing (known gBRCAm in a family member), it is recommended that pre-test counseling topics include options for screening and early detection, the benefits and disadvantages of risk-reducing surgery (including the extent of cancer risk reduction, risks associated with surgery, management of menopausal symptoms with RRSO, psychosocial and quality-of-life impacts, and life expectancy), the benefits and limitations of reconstructive surgery and reproductive options, and the psychological implications of pre-symptomatic diagnosis<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. Consideration is required with regard to reproductive concerns and the psychosocial impact of undergoing RRSO in gBRCAm carriers<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>.</p></sec></sec><sec id="Sec14"><title>gBRCAm counseling and testing in clinical practice</title><sec id="Sec15"><title>Implementation of guideline recommendations for gBRCAm counseling and testing</title><p id="Par21">Practice guidelines for genetic counseling and gBRCAm testing are predominantly based on personal and family history of breast, ovarian, pancreatic, and/or prostate cancer; young age at diagnosis; male breast cancer; and multiple tumors (breast and ovarian) in the same patient<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. More than 32 guidelines for gBRCAm testing relevant to breast cancer exist worldwide<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>, and the recommendations are often inconsistent. Many guidelines do not include recommendations for genetic counseling, or only provide counseling recommendations for patients who have been identified as carriers of gBRCAm<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Some guidelines recommend gBRCAm testing after genetic counseling and personalized risk assessment, and/or if the result is likely to influence the individual&#8217;s choice of primary treatment<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Some guidelines recommend testing based upon percentage risk of harboring a BRCA mutation, but there is a lack of consensus on the threshold used to determine whether an individual is eligible for genetics clinic referral/testing (10% vs 5%)<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>, and some guidelines propose testing all patients under certain circumstances (e.g., with ER-positive advanced breast cancer and resistance to endocrine therapy), considering that PARP inhibitors have a greater risk-benefit ratio than chemotherapy<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. There are limited treatment recommendations and algorithms for women with gBRCAm-associated advanced breast cancer<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Greater consensus and cohesion of guidelines would be useful for patients and the medical community covering the topics highlighted in Fig. <xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>gBRCAm counseling and testing in clinical practice.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e785" position="float" orientation="portrait" xlink:href="41523_2024_686_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec16"><title>Disparities in gBRCAm testing in clinical practice</title><p id="Par22">There has been a systemic underuse of gBRCAm testing over the past two decades, which has led to inappropriate and inconsistent testing and, consequently, missed opportunities for cancer prevention and management<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Historically, NCCN criteria have been seen to be the least restrictive of the models, identifying a larger percentage of carriers compared with other models. However, the complex nature of the NCCN criteria render them difficult to implement in real-world clinical practice<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, with low adherence rates reported<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. Expansion of NCCN criteria to include all women diagnosed at &#8804;65 years of age was shown to improve sensitivity of the selection criteria, without requiring testing of all women with breast cancer<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>.</p><p id="Par23">Although recent data from some centers and countries suggest widespread routine gBRCAm testing<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, a number of reports highlight the need for broader eligibility criteria for gBRCAm testing to ensure that more individuals can have access<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. Notably, patient eligibility for gBRCAm testing has been shown to vary depending on different testing criteria and recommendations, ranging from over 98% using recent guidelines published by the American Society of Breast Surgeons (ASBrS) to only around 30% eligibility using the Breast and Ovarian Analysis of Disease Incidence and Cancer Estimation Algorithm (BOADICEA) criteria<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Simplified, cost-effective eligibility criteria for gBRCAm testing, based on individual rather than family history criteria, have been proposed by the Mainstreaming Cancer Genetics (MCG) group. The five eligibility criteria include: (1) ovarian cancer diagnosis, (2) breast cancer diagnosed &#8804;45 years of age, (3) two primary breast cancers, both diagnosed &#8804;60 years of age, (4) TNBC diagnosis, and (5) male breast cancer diagnosis<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. In an analysis of different guidelines, using these criteria would have tested 92% of people and detected 100% of gBRCAm carriers<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. An additional sixth criteria (breast cancer, plus a parent, sibling, or child meeting any of the other criteria) further improved the eligibility rate to 97% (MCGplus)<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>, while expansion of NCCN criteria (v1.2020) to include individuals diagnosed at &#8804;65 years of age, as recommended by ASBrS, increased testing eligibility to include over 98% of BRCAm carriers<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Both the MCG and MCGplus criteria were deemed cost-effective, with cost-effective ratios of $1330 and $1225 per discounted quality-adjusted life year for the MCG and MCGplus criteria, respectively<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Additional studies have sought to investigate the cost-effectiveness of BRCA testing in all patients with breast cancer, with several studies conducted in countries such as Australia, China, Norway, Malaysia, the UK, and the US finding this to be a potentially cost-effective strategy<sup><xref ref-type="bibr" rid="CR61">61</xref>&#8211;<xref ref-type="bibr" rid="CR65">65</xref></sup>.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Eligibility for BRCAm testing using different testing criteria.</title><p>The graph shows estimates of patient eligibility for BRCA testing among BRCAm carriers. Data to the left of the dashed line is reproduced from a report in 2019 by the MCG group assessing rates of testing eligibility by different criteria<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>, while the bar to the right of the dashed line illustrates the result of an analysis by ASBrS published in 2020, examining the effect of including all individuals meeting NCCN criteria v1.2020 plus those diagnosed with breast cancer at &#8804;65 years<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. ASBrS, American Society of Breast Surgeons; BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Cancer Estimation Algorithm (&#8805;10 refers to a 10% or greater probability that a BRCA1 or BRCA2 mutation is present); MCG, Mainstreaming Cancer Genetics; MSS, Manchester Scoring System; NCCN, National Comprehensive Cancer Network<sup>&#174;</sup> (NCCN<sup>&#174;</sup>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e887" position="float" orientation="portrait" xlink:href="41523_2024_686_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>Traditional genetic counseling and testing pathway</title><p id="Par24">The traditional pathway of genetic testing involves individualized patient referral to the genetics department for the management of pre-test genetic counseling, consenting, sample acquisition, and return of results (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Pre-test counseling, and the process of informed consent, focuses on giving patients sufficient information about the test, its limitations, and the consequences (including psychological) of a positive result, to enable an informed decision as to whether or not to proceed<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Patients who test positive for gBRCAm receive post-test support from a geneticist/genetic counselor/expert<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup>.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Key steps and challenge points in traditional gBRCAm testing pathways.</title><p>MDT, multidisciplinary team.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e913" position="float" orientation="portrait" xlink:href="41523_2024_686_Fig4_HTML.jpg"/></fig></p><p id="Par25">Genetic professionals offering counseling include both medical genetic physicians (professionals with advanced training, such as an MD with a specialization in genetic medicine) and genetic counselors (professionals with a specialized Masters degree in genetic counseling)<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup>. Genetic counseling by a trained genetics clinician has been shown to improve patient knowledge, understanding, and satisfaction among patients<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>, and is recommended in multiple guidelines<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. While advantages of this type of care are clear, disadvantages include that it can be time-consuming, and a limited number of professionals are appropriately trained. When rapid access to test results is required to inform treatment decisions in a time-sensitive manner, especially for those undergoing upfront surgery, it may not be possible to maintain this workflow, and innovative alternatives may be required<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>.</p><p id="Par26">Although genetic counseling is recommended, a dearth of adequately trained professionals in this field may limit access<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>, with some countries imposing legal requirements for practicing genetic counseling<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Where possible, non-geneticist physicians might feel the need to counsel and test patients themselves without support, despite increasing demands on their time and shorter appointment times<sup><xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup>. Across Canada and the US, there are approximately 1.5 genetic counselors per 100,000 individuals, and it is estimated that double the workforce will be needed to meet future demands<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. There has been an increase in genetic counselors reporting the use of multiple types of delivery models, including telephone and telegenetics, with an aim of improving access and efficiency of genetic counseling; however, barriers remain that can hinder implementation of these models<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. In a large, US population-based study, only 62% of high-risk patients with newly diagnosed breast cancer who were tested had a genetic counselor session<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. Furthermore, 66% of all patients, and 81% of high-risk patients, wanted testing but only 29 and 53% received it, respectively<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. The most common reason for high-risk patients not being tested was &#8220;my doctor didn&#8217;t recommend it&#8221;<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. Wait times to see genetic specialists can also be substantial. In the UK, the Nottingham University Hospitals National Health Service (NHS) Trust reports wait times of 12&#8211;14 weeks for an initial appointment and 4&#8211;6 months to receive results<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. This highlights the need for alternative models of counseling and consenting of patients to ensure all eligible patients receive testing in a timely manner.</p><p id="Par27">Systemic and societal barriers can impede equitable access to the benefits of genetic testing. Suboptimal testing rates among individuals of low socioeconomic status have been largely attributed to perceived/actual financial costs of genetic testing, with patients and healthcare providers often unclear as to whether genetic counseling services and follow-up care are covered by health insurance<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup>. Strategies to improve testing rates in this patient demographic include the integration of genetic counselors into primary care settings to reduce travel time and costs to the patient<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>, and lobbying for expanded health insurance coverage for genetic counseling and testing services<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>.</p><p id="Par28">Reports from US ovarian and breast cancer centers have consistently found racial/ethnic disparity in access to genetic testing, with referral rates being higher for non-Hispanic White women than for women of other races<sup><xref ref-type="bibr" rid="CR80">80</xref>&#8211;<xref ref-type="bibr" rid="CR82">82</xref></sup>. Lower awareness of the genetic basis of risk, incomplete family history, and mistrust of medical confidentiality may contribute to racial/ethnic disparities in referrals for genetic testing<sup><xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR83">83</xref></sup>. In addition, the detection of pathogenic variants may be decreased, and variants of uncertain significance increased, in non-White individuals<sup><xref ref-type="bibr" rid="CR84">84</xref>&#8211;<xref ref-type="bibr" rid="CR86">86</xref></sup>, as genomic reference databases provide poor genetic representation of non-White populations<sup><xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup>. Whilst initiatives have been established to address gaps in the diversity of genomic data<sup><xref ref-type="bibr" rid="CR89">89</xref></sup>, additional strategies are required to increase genetic testing rates among non-White populations. These include the development of culturally and linguistically tailored educational material, extended appointment availability, increased training of primary care-based specialists to mitigate unconscious or implicit biases, and a drive to recruit and train more healthcare providers from minority backgrounds<sup><xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>.</p></sec><sec id="Sec18"><title>Mainstream genetic counseling and testing pathways</title><p id="Par29">In mainstream genetic testing pathways, medical oncology teams are responsible for pre-test genetic counseling, obtaining consent, scheduling the genetic test, and using the results to guide treatment decisions (Fig. <xref rid="Fig5" ref-type="fig">5</xref>)<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR91">91</xref>,<xref ref-type="bibr" rid="CR92">92</xref></sup>. Implementation of mainstream models has enabled more efficient testing of patients with ovarian cancer and has significantly increased the proportion of patients being offered genetic testing<sup><xref ref-type="bibr" rid="CR93">93</xref>&#8211;<xref ref-type="bibr" rid="CR95">95</xref></sup>.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Example gBRCAm testing pathway to illustrate the mainstream genetic testing pathway.</title><p>VUS, variant of uncertain significance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1073" position="float" orientation="portrait" xlink:href="41523_2024_686_Fig5_HTML.jpg"/></fig></p><p id="Par30">Mainstream genetic testing models for patients with breast cancer have also proven effective, with high pathogenic variant detection rates and a reduced burden on genetic services observed<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR76">76</xref></sup>. A Canadian study reported a significant decrease in wait time from referral to the return of genetic test results using an oncology clinic-based model compared with a traditional model in patients with breast or ovarian cancer (403 vs 191 days; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001)<sup><xref ref-type="bibr" rid="CR96">96</xref></sup>. Other studies support that oncologist-led mainstreaming results in increased testing uptake and shorter test-turnaround times<sup><xref ref-type="bibr" rid="CR97">97</xref>,<xref ref-type="bibr" rid="CR98">98</xref></sup>. A systematic review of 15 studies in patients with breast, ovarian, endometrial, or prostate cancer showed that turnaround times with the mainstream approach are lower than those with the traditional pathway, with results typically obtained 3&#8211;6 weeks after discussing and ordering the genetic test<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>. Another study in patients with breast cancer measured an 85% reduction in time to test result using the mainstream model compared with the traditional model (4 vs 25 weeks)<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. A mainstreaming program in Australia had successful uptake with a notable gBRCAm detection rate and a reduced burden on the center, enabling reallocation of resources to streamline the genetic testing process<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. Mainstream models also reduce genetic consultation requirements versus traditional models<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup>.</p><sec id="Sec19"><title>Perspectives of the multidisciplinary team</title><p id="Par31">Oncogenetic partnership models, in which clinical teams order genetic testing in collaboration with geneticists and implement counseling at both an individual and group level, have been shown to improve access to counseling and reduce turnaround times for genetic testing<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>. However, the feasibility of implementing new testing strategies may vary by region.</p><p id="Par32">As part of the MCG program in breast cancer in the UK and Malaysia, 100% of team members (12 oncologists, 8 surgeons, and 3 nurse specialists) reported feeling confident to approve patients for genetic testing, and believed that the process worked well<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Similar experiences have been reported among ovarian cancer teams<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR91">91</xref></sup>. However, another study surveying oncologists, clinical geneticists, and surgeons found that while oncologists and clinical geneticists were mainly positive about the introduction of mainstream approaches, surgeons were not keen to implement mainstream services in their breast clinic, feeling that they did not have the expertise, time, or capacity to undertake the extra responsibility, and that genetic testing did not have much relevance for their treatment decision-making<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>.</p><p id="Par33">Nurses play an integral role within the oncology team, with clinical nurse specialists often being the key point of contact for patients throughout the cancer pathway and thus ideally placed to deliver information on gBRCAm testing. A single-center UK study assessing the use of clinical nurse specialists in consenting patients with ovarian cancer for gBRCAm testing showed that there was no difference in patient-reported satisfaction compared with oncologist-led consenting, and nurses felt confident in counseling, consenting, and returning results<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. A specialist, nurse-led breast cancer MCG service established at the Nottingham Breast Institute, UK, has reduced wait time from the date of testing to the date of results to 36 days compared with an historical wait time of 4&#8211;6 months, while also delivering continuity of care for patients, releasing oncologists&#8217; time, and allowing oncologists and patients to consider treatment options at an earlier time point<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. The potential for nurses to play a role in decision coaching in healthy individuals who are carriers of gBRCAm is being explored, with preliminary results suggesting the approach is feasible<sup><xref ref-type="bibr" rid="CR101">101</xref>,<xref ref-type="bibr" rid="CR102">102</xref></sup>. We provide an educational guide for nurses to outline the role that nurses can play in the gBRCA testing pathway and support conversations around nurse-obtained consent (<xref rid="MOESM1" ref-type="media">supplementary information</xref><bold>:</bold>
<italic toggle="yes">Nurse consenting guide for germline BRCA testing</italic>).</p></sec><sec id="Sec20"><title>The patients&#8217; perspective</title><p id="Par34">Genetic testing in mainstream oncology units is widely accepted by patients<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR91">91</xref>,<xref ref-type="bibr" rid="CR103">103</xref>&#8211;<xref ref-type="bibr" rid="CR106">106</xref></sup>. In the MCG breast cancer program, 96% of patients were happy that genetic testing was performed by their cancer team<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Some patients reported a preference for their medical oncologist or their oncology nurse to deliver pre-test counseling, because medical oncologists could use the information gained through genetic testing for treatment decisions, and because nurses are more familiar with, and better understand, the individual patient experience<sup><xref ref-type="bibr" rid="CR105">105</xref></sup>.</p></sec><sec id="Sec21"><title>Educational needs for non-genetic specialists</title><p id="Par35">Ensuring appropriate training on an ongoing basis for those involved in consenting and arranging genetic testing is paramount to the success of mainstream gBRCAm testing<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. An early study evaluating patient experiences of gBRCAm testing in the US (all tumor types) found that the quality of information given to patients by non-certified genetic healthcare professionals (HCPs) was not as consistent as that given by certified genetic HCPs, with far fewer patients in mainstream testing versus traditional counseling recalling having had a pre-test discussion, and what that included<sup><xref ref-type="bibr" rid="CR107">107</xref></sup>. The types of training required by non-genetic specialists include generic consent training, plus specific genetics training, which involves learning how to identify eligible patients for gBRCAm testing, the relevance of gBRCAm testing, the significance for patients with a positive or negative result, the significance of a gBRCAm variant requiring evaluation, and implications of a positive test for family members<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Workshops designed to improve HCP knowledge and self-confidence have been shown to significantly enhance ability to overcome communication difficulties in relation to genetic testing and counseling<sup><xref ref-type="bibr" rid="CR108">108</xref></sup>. We provide educational guides to support healthcare providers in their understanding of the gBRCA testing and consenting pathway (<xref rid="MOESM1" ref-type="media">supplementary information</xref>: <italic toggle="yes">HCP guide to genetic counseling: Understanding germline BRCA testing and its clinical implications in breast cancer</italic> and <italic toggle="yes">Germline BRCA testing pathway infographic</italic>), as well as useful language to help explain the process to patients (<xref rid="MOESM1" ref-type="media">supplementary information</xref>: <italic toggle="yes">Patient-HCP flipbook: What you need to know about BRCA testing</italic>).</p></sec></sec><sec id="Sec22"><title>Use of digital tools</title><p id="Par36">Digital tools are being increasingly used across the genetic testing pathway for clinical assessment, family history taking, education, post-test counseling, and follow-up, and include web-based tools, mobile applications, chatbots, videos, and games<sup><xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR109">109</xref>,<xref ref-type="bibr" rid="CR110">110</xref></sup>. They have been shown to improve access to genetic testing (particularly for patients in under-served areas), reduce waiting times, enhance continuity of care, increase patient engagement, and free up time for other patient-centered consultations<sup><xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR110">110</xref></sup>. Digital tools are associated with positive patient outcomes, including increased knowledge and reduced decision conflict, and achieve similar patient outcomes to in-person consultations<sup><xref ref-type="bibr" rid="CR109">109</xref></sup>.</p><p id="Par37">There are no digital tools that offer a comprehensive solution across the entire genetic counseling and testing pathway, with most tools developed for use in the pre-test counseling phase only<sup><xref ref-type="bibr" rid="CR109">109</xref></sup>. The Genetics Navigator is currently in development and aims to supplement in-person consultations and support the full genetic testing pathway, including pre-test counseling, education, decision support, laboratory reporting, personalized return of results, and post-test counseling<sup><xref ref-type="bibr" rid="CR110">110</xref></sup>. A digital pathway has also been integrated into the UK NHS clinical, laboratory, and informatics systems for delivery of gBRCAm testing to cancer patients and has been piloted as part of the BRCA-DIRECT study<sup><xref ref-type="bibr" rid="CR111">111</xref></sup>. Results demonstrated that uptake of genetic testing using the digital pathway was non-inferior to those receiving pre-test information via telephone, with similarly good patient satisfaction and knowledge and low anxiety scores<sup><xref ref-type="bibr" rid="CR111">111</xref></sup>.</p></sec></sec><sec id="Sec23"><title>The future of genetic testing in breast cancer</title><sec id="Sec24"><title>Germline versus somatic mutation testing</title><p id="Par38">Genetic testing of tumor tissue has the potential to identify both germline and somatic pathogenic (or likely pathogenic) variants, and thus identify more people who might benefit from targeted therapies. Indeed, several studies have demonstrated clinical benefit with PARP inhibitor treatment for somatic BRCAm (sBRCAm) breast cancers<sup><xref ref-type="bibr" rid="CR112">112</xref>&#8211;<xref ref-type="bibr" rid="CR114">114</xref></sup>. High concordance between germline and tumor BRCAm testing in breast and ovarian cancer has been observed<sup><xref ref-type="bibr" rid="CR115">115</xref>&#8211;<xref ref-type="bibr" rid="CR120">120</xref></sup>; however, while sBRCAm and gBRCAm can be mutually exclusive in breast cancer, and not all mutation types can be detected by current clinical testing methods, it is possible that patients with metastatic breast cancer could benefit more from tumor testing than germline testing, as other abnormalities and targets could be identified<sup><xref ref-type="bibr" rid="CR121">121</xref>&#8211;<xref ref-type="bibr" rid="CR123">123</xref></sup>. For example, approvals of alpelisib plus fulvestrant for the treatment of <italic toggle="yes">PIK3CA</italic>m advanced or metastatic breast cancer<sup><xref ref-type="bibr" rid="CR124">124</xref></sup>, capivasertib plus fulvestrant for advanced or metastatic breast cancer with <italic toggle="yes">PIK3CA</italic>m, <italic toggle="yes">AKT1</italic>m, or <italic toggle="yes">PTEN</italic>m<sup><xref ref-type="bibr" rid="CR125">125</xref></sup>, and pembrolizumab for the treatment of unresectable or metastatic solid tumors of any type with high tumor mutational burden<sup><xref ref-type="bibr" rid="CR126">126</xref></sup> may have led to an increase in patient referrals for tumor testing using a gene panel assay. An increasing number of patients with BRCAm breast cancer could, therefore, receive an incidental positive result for BRCAm and be subsequently offered a gBRCA test to confirm the somatic or germline status, in accordance with NCCN Guidelines<sup>&#174;</sup><sup><xref ref-type="bibr" rid="CR21">21</xref></sup>.</p><p id="Par39">Parallel testing of normal and tumor material offers an alternative approach that allows direct differentiation of somatic versus germline pathogenic (or likely pathogenic) variants, leading to timely treatment selection and genetic counseling that may otherwise be delayed with germline- or tumor-only testing<sup><xref ref-type="bibr" rid="CR127">127</xref></sup>. Somatic testing alone would not distinguish between germline and somatic pathogenic (or likely pathogenic) variants, and thus may not be useful for determining future surveillance/surgery options for the patient, and may not benefit family members<sup><xref ref-type="bibr" rid="CR128">128</xref></sup>. Therefore, an increasing number of centers are moving toward parallel testing for patients with a breast cancer diagnosis<sup><xref ref-type="bibr" rid="CR127">127</xref></sup>. Analysis of circulating tumor DNA has the potential to identify both somatic and germline variants, and may offer a non-invasive alternative to tissue testing<sup><xref ref-type="bibr" rid="CR129">129</xref></sup>.</p></sec><sec id="Sec25"><title>Genetic testing beyond BRCA</title><p id="Par40">Panel testing allows for the screening of multiple genes beyond <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> that may be associated with tumor development and/or treatment response<sup><xref ref-type="bibr" rid="CR130">130</xref></sup>. For example, several other factors in the homologous recombination pathway have emerged as clinically relevant in surgical and treatment decision-making<sup><xref ref-type="bibr" rid="CR131">131</xref>,<xref ref-type="bibr" rid="CR132">132</xref></sup>. Pathogenic variants in breast cancer susceptibility genes beyond <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> are increasingly being considered in clinical trials with targeted therapies<sup><xref ref-type="bibr" rid="CR113">113</xref>,<xref ref-type="bibr" rid="CR133">133</xref>,<xref ref-type="bibr" rid="CR134">134</xref></sup> and further recommendations for risk reduction, screening, and treatment strategies for carriers of these variants are being incorporated into clinical practice guideline updates and risk assessment tools<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. For example, current NCCN Guidelines recommend discussion of risk-reducing mastectomy with patients found to harbor pathogenic or likely pathogenic variants in <italic toggle="yes">CDH1, PALB2, PTEN, STK11</italic>, or <italic toggle="yes">TP53</italic>, and consideration of RRSO at 45&#8211;50 years of age in patients with pathogenic or likely pathogenic variants in <italic toggle="yes">PALB2</italic>, <italic toggle="yes">RAD51C</italic>, or <italic toggle="yes">RAD51D</italic><sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. The web-based CanRisk tool, which integrates the presence of pathogenic variants in eight breast cancer susceptibility genes with several other risk factors to estimate the personal risk of breast cancer, is currently endorsed by multiple clinical guidelines<sup><xref ref-type="bibr" rid="CR135">135</xref>,<xref ref-type="bibr" rid="CR136">136</xref></sup>.</p><p id="Par41">To summarize, advancements in patient information and care, in particular the introduction of PARP inhibitors for the treatment of breast and other cancers, have resulted in a substantial increase in demand for genetic testing. This demand is supported by the evidence that gBRCA testing in breast cancer management is a cost-effective strategy. However, without a substantial increase in personnel, traditional, genetics-led models of counseling and consenting are unable to meet the growing demand. A case can be made to increase the number of genetically trained HCPs but, even if possible, there will be a certain time lag before they are available. Mainstreaming models and the use of digital tools have demonstrated potential in providing efficient, patient-centered care that can meet the increasing needs of patients. In the future, we may see a move toward more widespread and comprehensive testing for germline and tumor alterations, raising further challenges as to how this can be effectively incorporated into comprehensive cancer care.</p></sec></sec><sec id="Sec26" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41523_2024_686_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary information</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41523-024-00686-8.</p></sec><ack><title>Acknowledgements</title><p>This review article and materials presented herein were conceived by the authors following a series of meetings by the BRCA Testing in Breast Cancer Expert Panel (sponsored by AstraZeneca). Medical writing assistance, under the direction of the authors, was provided by Alison Lovibond PhD from BOLDSCIENCE Inc. funded by AstraZeneca UK, Plc. and Merck &amp; Co., Inc., Kenilworth, NJ, USA, in accordance with Good Publication Practice 2022 guidelines. All images of individuals in this publication were obtained from stock photographs owned by AstraZeneca.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>P.D., C.J., and S.P-S. conceptualized and designed the review. P.D., C.J., S-A.I., K.K.H., C-F.L., S.U., and S.P-S. contributed to the literature search, writing, editing, and review of the manuscript. All authors critically revised and approved the final manuscript.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par42">C.J. has received consultancy fees from AstraZeneca, Daiichi Sankyo, Eli Lilly &amp; Co., Novartis, and Roche; received support for travel or to attend meetings from Daiichi Sankyo, Pierre Fabre, and Roche; and has an unpaid role on the AGO Task Force for treatment recommendations on diagnosis and therapy in breast cancer. K.K.H. has received research funding to her institution from Cairn Surgical, Eli Lilly &amp; Co., and Lumicell; is an Editor for <italic toggle="yes">Current Breast Cancer Reports</italic> (Springer); has received consultancy fees from Armada Health and honoraria for lectures and educational events from AstraZeneca. P.D. has received grants to his institution from Bristol Myers Squibb, MSD, and Roche to support patient activities; consultancy fees to his institution from AstraZeneca, MSD, and Roche; payments for speaking engagements or educational activities to his institution from AstraZeneca; and support to his institution for attending meetings or travel from Roche. S-A.I. has received grants from AstraZeneca, Boryung, Eisai, Daewoong Pharmaceutical, Daiichi Sankyo, Pfizer, and Roche; and consultancy fees from AstraZeneca, Bertis, Daiichi Sankyo, Eisai, Eli Lilly &amp; Co, GSK, Hanmi, Idience, MSD, Novartis, Pfizer, and Roche. S.P-S. has received an independent research grant from Pfizer; consultancy fees to their institution from AstraZeneca, Daiichi Sankyo, Eli Lilly &amp; Co., Gilead, Medison, MSD, Novartis, Pfizer, Roche, and Sharing Progress in Cancer Care; support to their institution for attending meetings and/or travel from Gilead, Pfizer, and Roche; and is the Subject Editor for breast cancer and on the clinical practice guideline committee of the European Society for Medical Oncology (ESMO). S.U. has received honoraria to her institution for speaking engagements or educational events. C-F.L. has no competing interests to disclose.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wooster</surname><given-names>R</given-names></name><etal/></person-group><article-title>Identification of the breast cancer susceptibility gene BRCA2</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>789</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1038/378789a0</pub-id><pub-id pub-id-type="pmid">8524414</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. <italic toggle="yes">Nature</italic><bold>378</bold>, 789&#8211;792 (1995).<pub-id pub-id-type="pmid">8524414</pub-id><pub-id pub-id-type="doi">10.1038/378789a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albertsen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Genetic mapping of the BRCA1 region on chromosome 17q21</article-title><source>Am. J. Hum. Genet.</source><year>1994</year><volume>54</volume><fpage>516</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">8116621</pub-id><pub-id pub-id-type="pmcid">PMC1918118</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Albertsen, H. et al. Genetic mapping of the BRCA1 region on chromosome 17q21. <italic toggle="yes">Am. J. Hum. Genet.</italic><bold>54</bold>, 516&#8211;525 (1994).<pub-id pub-id-type="pmid">8116621</pub-id><pub-id pub-id-type="pmcid">PMC1918118</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>R</given-names></name><name name-style="western"><surname>Chun</surname><given-names>J</given-names></name><name name-style="western"><surname>Powell</surname><given-names>SN</given-names></name></person-group><article-title>BRCA1 and BRCA2: different roles in a common pathway of genome protection</article-title><source>Nat. Rev. Cancer</source><year>2011</year><volume>12</volume><fpage>68</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/nrc3181</pub-id><pub-id pub-id-type="pmid">22193408</pub-id><pub-id pub-id-type="pmcid">PMC4972490</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Roy, R., Chun, J. &amp; Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. <italic toggle="yes">Nat. Rev. Cancer</italic><bold>12</bold>, 68&#8211;78 (2011).<pub-id pub-id-type="pmid">22193408</pub-id><pub-id pub-id-type="doi">10.1038/nrc3181</pub-id><pub-id pub-id-type="pmcid">PMC4972490</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L. &amp; Ming, H. V. Y. PARP inhibitors in breast and ovarian cancer. <italic toggle="yes">Cancers</italic><bold>15</bold>, 2357 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15082357</pub-id><pub-id pub-id-type="pmcid">PMC10137187</pub-id><pub-id pub-id-type="pmid">37190285</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>523</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1706450</pub-id><pub-id pub-id-type="pmid">28578601</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. <italic toggle="yes">N. Engl. J. Med.</italic><bold>377</bold>, 523&#8211;533 (2017).<pub-id pub-id-type="pmid">28578601</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1706450</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Litton</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Talazoparib in patients with advanced breast cancer and a germline BRCA mutation</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>753</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1802905</pub-id><pub-id pub-id-type="pmid">30110579</pub-id><pub-id pub-id-type="pmcid">PMC10600918</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. <italic toggle="yes">N. Engl. J. Med.</italic><bold>379</bold>, 753&#8211;763 (2018).<pub-id pub-id-type="pmid">30110579</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1802905</pub-id><pub-id pub-id-type="pmcid">PMC10600918</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geyer</surname><given-names>CE</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer</article-title><source>Ann. Oncol.</source><year>2022</year><volume>33</volume><fpage>1250</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.09.159</pub-id><pub-id pub-id-type="pmid">36228963</pub-id><pub-id pub-id-type="pmcid">PMC10207856</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Geyer, C. E. Jr et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. <italic toggle="yes">Ann. Oncol.</italic><bold>33</bold>, 1250&#8211;1268 (2022).<pub-id pub-id-type="pmid">36228963</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2022.09.159</pub-id><pub-id pub-id-type="pmcid">PMC10207856</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheinberg</surname><given-names>T</given-names></name><etal/></person-group><article-title>Mainstream consent programs for genetic counseling in cancer patients: a systematic review</article-title><source>Asia Pac. J. Clin. Oncol.</source><year>2021</year><volume>17</volume><fpage>163</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1111/ajco.13334</pub-id><pub-id pub-id-type="pmid">32309911</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Scheinberg, T. et al. Mainstream consent programs for genetic counseling in cancer patients: a systematic review. <italic toggle="yes">Asia Pac. J. Clin. Oncol.</italic><bold>17</bold>, 163&#8211;177 (2021).<pub-id pub-id-type="pmid">32309911</pub-id><pub-id pub-id-type="doi">10.1111/ajco.13334</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Percival</surname><given-names>N</given-names></name><etal/></person-group><article-title>The integration of BRCA testing into oncology clinics</article-title><source>Br. J. Nurs.</source><year>2016</year><volume>25</volume><fpage>690</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.12968/bjon.2016.25.12.690</pub-id><pub-id pub-id-type="pmid">27345073</pub-id><pub-id pub-id-type="pmcid">PMC5993185</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Percival, N. et al. The integration of BRCA testing into oncology clinics. <italic toggle="yes">Br. J. Nurs.</italic><bold>25</bold>, 690&#8211;694 (2016).<pub-id pub-id-type="pmid">27345073</pub-id><pub-id pub-id-type="doi">10.12968/bjon.2016.25.12.690</pub-id><pub-id pub-id-type="pmcid">PMC5993185</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dusic</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Barriers, interventions, and recommendations: improving the genetic testing landscape</article-title><source>Front. Digit. Health</source><year>2022</year><volume>4</volume><fpage>961128</fpage><pub-id pub-id-type="doi">10.3389/fdgth.2022.961128</pub-id><pub-id pub-id-type="pmid">36386046</pub-id><pub-id pub-id-type="pmcid">PMC9665160</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Dusic, E. J. et al. Barriers, interventions, and recommendations: improving the genetic testing landscape. <italic toggle="yes">Front. Digit. Health</italic><bold>4</bold>, 961128 (2022).<pub-id pub-id-type="pmid">36386046</pub-id><pub-id pub-id-type="doi">10.3389/fdgth.2022.961128</pub-id><pub-id pub-id-type="pmcid">PMC9665160</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sessa</surname><given-names>C</given-names></name><etal/></person-group><article-title>Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline</article-title><source>Ann. Oncol.</source><year>2023</year><volume>34</volume><fpage>33</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.10.004</pub-id><pub-id pub-id-type="pmid">36307055</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Sessa, C. et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. <italic toggle="yes">Ann. Oncol.</italic><bold>34</bold>, 33&#8211;47 (2023).<pub-id pub-id-type="pmid">36307055</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2022.10.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ford</surname><given-names>D</given-names></name><etal/></person-group><article-title>Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium</article-title><source>Am. J. Hum. Genet.</source><year>1998</year><volume>62</volume><fpage>676</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1086/301749</pub-id><pub-id pub-id-type="pmid">9497246</pub-id><pub-id pub-id-type="pmcid">PMC1376944</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Ford, D. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. <italic toggle="yes">Am. J. Hum. Genet.</italic><bold>62</bold>, 676&#8211;689 (1998).<pub-id pub-id-type="pmid">9497246</pub-id><pub-id pub-id-type="doi">10.1086/301749</pub-id><pub-id pub-id-type="pmcid">PMC1376944</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuchenbaecker</surname><given-names>KB</given-names></name><etal/></person-group><article-title>Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers</article-title><source>JAMA</source><year>2017</year><volume>317</volume><fpage>2402</fpage><lpage>2416</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.7112</pub-id><pub-id pub-id-type="pmid">28632866</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. <italic toggle="yes">JAMA</italic><bold>317</bold>, 2402&#8211;2416 (2017).<pub-id pub-id-type="pmid">28632866</pub-id><pub-id pub-id-type="doi">10.1001/jama.2017.7112</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambertini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants</article-title><source>NPJ Breast Cancer</source><year>2021</year><volume>7</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41523-021-00224-w</pub-id><pub-id pub-id-type="pmid">33579978</pub-id><pub-id pub-id-type="pmcid">PMC7880991</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Lambertini, M. et al. Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <italic toggle="yes">NPJ Breast Cancer</italic><bold>7</bold>, 16 (2021).<pub-id pub-id-type="pmid">33579978</pub-id><pub-id pub-id-type="doi">10.1038/s41523-021-00224-w</pub-id><pub-id pub-id-type="pmcid">PMC7880991</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>&#174;</sup>) for Breast Cancer Version 2.2024. &#169; National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 17, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.</mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Consensus conference on breast conservation, Milan, Italy, April 28-May 1, 2005</article-title><source>Breast J.</source><year>2006</year><volume>12</volume><fpage>398</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1111/j.1075-122X.2006.00292.x</pub-id><pub-id pub-id-type="pmid">16848863</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Schwartz, G. F. et al. Consensus conference on breast conservation, Milan, Italy, April 28-May 1, 2005. <italic toggle="yes">Breast J.</italic><bold>12</bold>, 398&#8211;407 (2006).<pub-id pub-id-type="pmid">16848863</pub-id><pub-id pub-id-type="doi">10.1111/j.1075-122X.2006.00292.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tung</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>2080</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.00299</pub-id><pub-id pub-id-type="pmid">32243226</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Tung, N. M. et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. <italic toggle="yes">J. Clin. Oncol.</italic><bold>38</bold>, 2080&#8211;2106 (2020).<pub-id pub-id-type="pmid">32243226</pub-id><pub-id pub-id-type="doi">10.1200/JCO.20.00299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheepens</surname><given-names>JCC</given-names></name><name name-style="western"><surname>Veer</surname><given-names>LV</given-names></name><name name-style="western"><surname>Esserman</surname><given-names>L</given-names></name><name name-style="western"><surname>Belkora</surname><given-names>J</given-names></name><name name-style="western"><surname>Mukhtar</surname><given-names>RA</given-names></name></person-group><article-title>Contralateral prophylactic mastectomy: a narrative review of the evidence and acceptability</article-title><source>Breast</source><year>2021</year><volume>56</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2021.02.003</pub-id><pub-id pub-id-type="pmid">33621798</pub-id><pub-id pub-id-type="pmcid">PMC7907889</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Scheepens, J. C. C., Veer, L. V., Esserman, L., Belkora, J. &amp; Mukhtar, R. A. Contralateral prophylactic mastectomy: a narrative review of the evidence and acceptability. <italic toggle="yes">Breast</italic><bold>56</bold>, 61&#8211;69 (2021).<pub-id pub-id-type="pmid">33621798</pub-id><pub-id pub-id-type="doi">10.1016/j.breast.2021.02.003</pub-id><pub-id pub-id-type="pmcid">PMC7907889</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis</article-title><source>Cancer Cell Int.</source><year>2021</year><volume>21</volume><fpage>512</fpage><pub-id pub-id-type="doi">10.1186/s12935-021-02194-2</pub-id><pub-id pub-id-type="pmid">34563200</pub-id><pub-id pub-id-type="pmcid">PMC8466340</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Jia, Z. et al. Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis. <italic toggle="yes">Cancer Cell Int.</italic><bold>21</bold>, 512 (2021).<pub-id pub-id-type="pmid">34563200</pub-id><pub-id pub-id-type="doi">10.1186/s12935-021-02194-2</pub-id><pub-id pub-id-type="pmcid">PMC8466340</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Sprundel</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers</article-title><source>Br. J. Cancer</source><year>2005</year><volume>93</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6602703</pub-id><pub-id pub-id-type="pmid">16052221</pub-id><pub-id pub-id-type="pmcid">PMC2361560</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">van Sprundel, T. C. et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. <italic toggle="yes">Br. J. Cancer</italic><bold>93</bold>, 287&#8211;292 (2005).<pub-id pub-id-type="pmid">16052221</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6602703</pub-id><pub-id pub-id-type="pmcid">PMC2361560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&#174;) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V.3.2024. &#169; National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 17, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name></person-group><article-title>Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: a systematic review and meta-analysis</article-title><source>Eur. J. Surg. Oncol.</source><year>2022</year><volume>48</volume><fpage>1209</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2022.02.019</pub-id><pub-id pub-id-type="pmid">35216860</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wang, Y., Song, Z., Zhang, S., Wang, X. &amp; Li, P. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: a systematic review and meta-analysis. <italic toggle="yes">Eur. J. Surg. Oncol.</italic><bold>48</bold>, 1209&#8211;1216 (2022).<pub-id pub-id-type="pmid">35216860</pub-id><pub-id pub-id-type="doi">10.1016/j.ejso.2022.02.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metcalfe</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers</article-title><source>JAMA Oncol.</source><year>2015</year><volume>1</volume><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.0658</pub-id><pub-id pub-id-type="pmid">26181175</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Metcalfe, K. et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. <italic toggle="yes">JAMA Oncol.</italic><bold>1</bold>, 306&#8211;313 (2015).<pub-id pub-id-type="pmid">26181175</pub-id><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.0658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terry</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk</article-title><source>J. Natl Cancer Inst.</source><year>2019</year><volume>111</volume><fpage>331</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1093/jnci/djy182</pub-id><pub-id pub-id-type="pmid">30496449</pub-id><pub-id pub-id-type="pmcid">PMC6410936</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Terry, M. B. et al. Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk. <italic toggle="yes">J. Natl Cancer Inst.</italic><bold>111</bold>, 331&#8211;334 (2019).<pub-id pub-id-type="pmid">30496449</pub-id><pub-id pub-id-type="doi">10.1093/jnci/djy182</pub-id><pub-id pub-id-type="pmcid">PMC6410936</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Heemskerk-Gerritsen, B. A. et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. <italic toggle="yes">J. Natl Cancer Inst.</italic><bold>107</bold>, djv033 (2015).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djv033</pub-id><pub-id pub-id-type="pmid">25788320</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hahnen</surname><given-names>E</given-names></name><etal/></person-group><article-title>Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial</article-title><source>JAMA Oncol.</source><year>2017</year><volume>3</volume><fpage>1378</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.1007</pub-id><pub-id pub-id-type="pmid">28715532</pub-id><pub-id pub-id-type="pmcid">PMC5710508</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Hahnen, E. et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. <italic toggle="yes">JAMA Oncol.</italic><bold>3</bold>, 1378&#8211;1385 (2017).<pub-id pub-id-type="pmid">28715532</pub-id><pub-id pub-id-type="doi">10.1001/jamaoncol.2017.1007</pub-id><pub-id pub-id-type="pmcid">PMC5710508</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tutt</surname><given-names>A</given-names></name><etal/></person-group><article-title>Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial</article-title><source>Nat. Med.</source><year>2018</year><volume>24</volume><fpage>628</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0009-7</pub-id><pub-id pub-id-type="pmid">29713086</pub-id><pub-id pub-id-type="pmcid">PMC6372067</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Tutt, A. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <italic toggle="yes">Nat. Med.</italic><bold>24</bold>, 628&#8211;637 (2018).<pub-id pub-id-type="pmid">29713086</pub-id><pub-id pub-id-type="doi">10.1038/s41591-018-0009-7</pub-id><pub-id pub-id-type="pmcid">PMC6372067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pohl-Rescigno</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial</article-title><source>JAMA Oncol.</source><year>2020</year><volume>6</volume><fpage>744</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2020.0007</pub-id><pub-id pub-id-type="pmid">32163106</pub-id><pub-id pub-id-type="pmcid">PMC7068666</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Pohl-Rescigno, E. et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. <italic toggle="yes">JAMA Oncol.</italic><bold>6</bold>, 744&#8211;748 (2020).<pub-id pub-id-type="pmid">32163106</pub-id><pub-id pub-id-type="doi">10.1001/jamaoncol.2020.0007</pub-id><pub-id pub-id-type="pmcid">PMC7068666</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><etal/></person-group><article-title>BRCA1/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the GeparQuinto study</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>2281</fpage><lpage>2287</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.77.2285</pub-id><pub-id pub-id-type="pmid">29791287</pub-id><pub-id pub-id-type="pmcid">PMC6067803</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Fasching, P. A. et al. BRCA1/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the GeparQuinto study. <italic toggle="yes">J. Clin. Oncol.</italic><bold>36</bold>, 2281&#8211;2287 (2018).<pub-id pub-id-type="pmid">29791287</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2017.77.2285</pub-id><pub-id pub-id-type="pmcid">PMC6067803</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loibl</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</article-title><source>Ann. Oncol.</source><year>2024</year><volume>35</volume><fpage>159</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2023.11.016</pub-id><pub-id pub-id-type="pmid">38101773</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Loibl, S. et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <italic toggle="yes">Ann. Oncol.</italic><bold>35</bold>, 159&#8211;182 (2024).<pub-id pub-id-type="pmid">38101773</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2023.11.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loibl</surname><given-names>S</given-names></name><etal/></person-group><article-title>Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2018</year><volume>19</volume><fpage>497</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30111-6</pub-id><pub-id pub-id-type="pmid">29501363</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Loibl, S. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. <italic toggle="yes">Lancet Oncol.</italic><bold>19</bold>, 497&#8211;509 (2018).<pub-id pub-id-type="pmid">29501363</pub-id><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30111-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caramelo</surname><given-names>O</given-names></name><etal/></person-group><article-title>Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis</article-title><source>Hered. Cancer Clin. Pract.</source><year>2022</year><volume>20</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s13053-022-00242-0</pub-id><pub-id pub-id-type="pmid">36085046</pub-id><pub-id pub-id-type="pmcid">PMC9463858</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Caramelo, O. et al. Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis. <italic toggle="yes">Hered. Cancer Clin. Pract.</italic><bold>20</bold>, 34 (2022).<pub-id pub-id-type="pmid">36085046</pub-id><pub-id pub-id-type="doi">10.1186/s13053-022-00242-0</pub-id><pub-id pub-id-type="pmcid">PMC9463858</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tung</surname><given-names>N</given-names></name><etal/></person-group><article-title>TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial)</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>1539</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.03292</pub-id><pub-id pub-id-type="pmid">32097092</pub-id><pub-id pub-id-type="pmcid">PMC8462533</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Tung, N. et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). <italic toggle="yes">J. Clin. Oncol.</italic><bold>38</bold>, 1539&#8211;1548 (2020).<pub-id pub-id-type="pmid">32097092</pub-id><pub-id pub-id-type="doi">10.1200/JCO.19.03292</pub-id><pub-id pub-id-type="pmcid">PMC8462533</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metzger-Filho</surname><given-names>O</given-names></name><etal/></person-group><article-title>Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness</article-title><source>NPJ Breast Cancer</source><year>2021</year><volume>7</volume><fpage>142</fpage><pub-id pub-id-type="doi">10.1038/s41523-021-00349-y</pub-id><pub-id pub-id-type="pmid">34764307</pub-id><pub-id pub-id-type="pmcid">PMC8586340</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Metzger-Filho, O. et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. <italic toggle="yes">NPJ Breast Cancer</italic><bold>7</bold>, 142 (2021).<pub-id pub-id-type="pmid">34764307</pub-id><pub-id pub-id-type="doi">10.1038/s41523-021-00349-y</pub-id><pub-id pub-id-type="pmcid">PMC8586340</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>ME</given-names></name><etal/></person-group><article-title>OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician&#8217;s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer</article-title><source>Eur. J. Cancer</source><year>2023</year><volume>184</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2023.01.031</pub-id><pub-id pub-id-type="pmid">36893711</pub-id><pub-id pub-id-type="pmcid">PMC10585240</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Robson, M. E. et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician&#8217;s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. <italic toggle="yes">Eur. J. Cancer</italic><bold>184</bold>, 39&#8211;47 (2023).<pub-id pub-id-type="pmid">36893711</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2023.01.031</pub-id><pub-id pub-id-type="pmcid">PMC10585240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>ME</given-names></name><etal/></person-group><article-title>OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician&#8217;s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz012</pub-id><pub-id pub-id-type="pmid">30689707</pub-id><pub-id pub-id-type="pmcid">PMC6503629</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Robson, M. E. et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician&#8217;s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. <italic toggle="yes">Ann. Oncol.</italic><bold>30</bold>, 558&#8211;566 (2019).<pub-id pub-id-type="pmid">30689707</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdz012</pub-id><pub-id pub-id-type="pmcid">PMC6503629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Litton</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial</article-title><source>Ann. Oncol.</source><year>2020</year><volume>31</volume><fpage>1526</fpage><lpage>1535</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.08.2098</pub-id><pub-id pub-id-type="pmid">32828825</pub-id><pub-id pub-id-type="pmcid">PMC10649377</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Litton, J. K. et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. <italic toggle="yes">Ann. Oncol.</italic><bold>31</bold>, 1526&#8211;1535 (2020).<pub-id pub-id-type="pmid">32828825</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2020.08.2098</pub-id><pub-id pub-id-type="pmcid">PMC10649377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tutt</surname><given-names>ANJ</given-names></name><etal/></person-group><article-title>Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>2394</fpage><lpage>2405</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2105215</pub-id><pub-id pub-id-type="pmid">34081848</pub-id><pub-id pub-id-type="pmcid">PMC9126186</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. <italic toggle="yes">N. Engl. J. Med.</italic><bold>384</bold>, 2394&#8211;2405 (2021).<pub-id pub-id-type="pmid">34081848</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2105215</pub-id><pub-id pub-id-type="pmcid">PMC9126186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)</article-title><source>Ann. Oncol.</source><year>2021</year><volume>32</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.10.471</pub-id><pub-id pub-id-type="pmid">33098995</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Fasching, P. A. et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). <italic toggle="yes">Ann. Oncol.</italic><bold>32</bold>, 49&#8211;57 (2021).<pub-id pub-id-type="pmid">33098995</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2020.10.471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Litton</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase II study</article-title><source>Oncologist</source><year>2023</year><volume>28</volume><fpage>845</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyad139</pub-id><pub-id pub-id-type="pmid">37318349</pub-id><pub-id pub-id-type="pmcid">PMC10546823</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Litton, J. K. et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase II study. <italic toggle="yes">Oncologist</italic><bold>28</bold>, 845&#8211;855 (2023).<pub-id pub-id-type="pmid">37318349</pub-id><pub-id pub-id-type="doi">10.1093/oncolo/oyad139</pub-id><pub-id pub-id-type="pmcid">PMC10546823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balma&#241;a</surname><given-names>J</given-names></name><etal/></person-group><article-title>Abstract OT2-18-02: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer</article-title><source>Cancer Res.</source><year>2023</year><volume>83</volume><fpage>OT2-18-02</fpage><lpage>OT12-18-02</lpage><pub-id pub-id-type="doi">10.1158/1538-7445.SABCS22-OT2-18-02</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Balma&#241;a, J. et al. Abstract OT2-18-02: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer. <italic toggle="yes">Cancer Res.</italic><bold>83</bold>, OT2-18-02&#8211;OT12-18-02 (2023).<pub-id pub-id-type="doi">10.1158/1538-7445.SABCS22-OT2-18-02</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardoso</surname><given-names>F</given-names></name><etal/></person-group><article-title>5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)</article-title><source>Ann. Oncol.</source><year>2020</year><volume>31</volume><fpage>1623</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.09.010</pub-id><pub-id pub-id-type="pmid">32979513</pub-id><pub-id pub-id-type="pmcid">PMC7510449</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <italic toggle="yes">Ann. Oncol.</italic><bold>31</bold>, 1623&#8211;1649 (2020).<pub-id pub-id-type="pmid">32979513</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2020.09.010</pub-id><pub-id pub-id-type="pmcid">PMC7510449</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slamon</surname><given-names>D</given-names></name><etal/></person-group><article-title>Ribociclib and endocrine therapy as adjuvant treatment in patients with HR./HER2- early breast cancer: primary results from the phase III NATALEE trial</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>LBA500</fpage><pub-id pub-id-type="doi">10.1200/JCO.2023.41.17_suppl.LBA500</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Slamon, D. et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR./HER2- early breast cancer: primary results from the phase III NATALEE trial. <italic toggle="yes">J. Clin. Oncol.</italic><bold>41</bold>, LBA500 (2023).<pub-id pub-id-type="doi">10.1200/JCO.2023.41.17_suppl.LBA500</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curigliano</surname><given-names>G</given-names></name><etal/></person-group><article-title>Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for fhe Primary Therapy of Individuals with Early Breast Cancer 2023</article-title><source>Ann. Oncol.</source><year>2023</year><volume>34</volume><fpage>970</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2023.08.017</pub-id><pub-id pub-id-type="pmid">37683978</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Curigliano, G. et al. Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for fhe Primary Therapy of Individuals with Early Breast Cancer 2023. <italic toggle="yes">Ann. Oncol.</italic><bold>34</bold>, 970&#8211;986 (2023).<pub-id pub-id-type="pmid">37683978</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2023.08.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>JM</given-names></name><etal/></person-group><article-title>A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status</article-title><source>Oncol. Ther.</source><year>2021</year><volume>9</volume><fpage>575</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1007/s40487-021-00162-4</pub-id><pub-id pub-id-type="pmid">34308518</pub-id><pub-id pub-id-type="pmcid">PMC8593114</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Collins, J. M. et al. A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status. <italic toggle="yes">Oncol. Ther.</italic><bold>9</bold>, 575&#8211;589 (2021).<pub-id pub-id-type="pmid">34308518</pub-id><pub-id pub-id-type="doi">10.1007/s40487-021-00162-4</pub-id><pub-id pub-id-type="pmcid">PMC8593114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer</article-title><source>Genome Med.</source><year>2023</year><volume>15</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/s13073-023-01201-7</pub-id><pub-id pub-id-type="pmid">37475004</pub-id><pub-id pub-id-type="pmcid">PMC10360358</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Park, Y. H. et al. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. <italic toggle="yes">Genome Med.</italic><bold>15</bold>, 55 (2023).<pub-id pub-id-type="pmid">37475004</pub-id><pub-id pub-id-type="doi">10.1186/s13073-023-01201-7</pub-id><pub-id pub-id-type="pmcid">PMC10360358</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruno</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cyclin-dependent kinase 4/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair-related genes</article-title><source>JCO Precis. Oncol.</source><year>2022</year><volume>6</volume><fpage>e2100140</fpage><pub-id pub-id-type="doi">10.1200/PO.21.00140</pub-id><pub-id pub-id-type="pmid">35235412</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Bruno, L. et al. Cyclin-dependent kinase 4/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair-related genes. <italic toggle="yes">JCO Precis. Oncol.</italic><bold>6</bold>, e2100140 (2022).<pub-id pub-id-type="pmid">35235412</pub-id><pub-id pub-id-type="doi">10.1200/PO.21.00140</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Antr&#225;s, J. F. et al. Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors. <italic toggle="yes">J. Clin. Oncol.</italic><bold>41</bold>, 1075 (2023).</mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy</article-title><source>Breast Cancer Res. Treat.</source><year>2022</year><volume>196</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1007/s10549-022-06566-8</pub-id><pub-id pub-id-type="pmid">36070058</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Park, S. Y. et al. Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy. <italic toggle="yes">Breast Cancer Res. Treat.</italic><bold>196</bold>, 121&#8211;128 (2022).<pub-id pub-id-type="pmid">36070058</pub-id><pub-id pub-id-type="doi">10.1007/s10549-022-06566-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emens</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study</article-title><source>J. Natl Cancer Inst.</source><year>2021</year><volume>113</volume><fpage>1005</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1093/jnci/djab004</pub-id><pub-id pub-id-type="pmid">33523233</pub-id><pub-id pub-id-type="pmcid">PMC8328980</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Emens, L. A. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. <italic toggle="yes">J. Natl Cancer Inst.</italic><bold>113</bold>, 1005&#8211;1016 (2021).<pub-id pub-id-type="pmid">33523233</pub-id><pub-id pub-id-type="doi">10.1093/jnci/djab004</pub-id><pub-id pub-id-type="pmcid">PMC8328980</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forbes</surname><given-names>C</given-names></name><name name-style="western"><surname>Fayter</surname><given-names>D</given-names></name><name name-style="western"><surname>de Kock</surname><given-names>S</given-names></name><name name-style="western"><surname>Quek</surname><given-names>RG</given-names></name></person-group><article-title>A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer</article-title><source>Cancer Manag. Res.</source><year>2019</year><volume>11</volume><fpage>2321</fpage><lpage>2337</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S189627</pub-id><pub-id pub-id-type="pmid">30962720</pub-id><pub-id pub-id-type="pmcid">PMC6434912</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Forbes, C., Fayter, D., de Kock, S. &amp; Quek, R. G. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. <italic toggle="yes">Cancer Manag. Res.</italic><bold>11</bold>, 2321&#8211;2337 (2019).<pub-id pub-id-type="pmid">30962720</pub-id><pub-id pub-id-type="doi">10.2147/CMAR.S189627</pub-id><pub-id pub-id-type="pmcid">PMC6434912</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Bedrosian, I. et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline. <italic toggle="yes">J. Clin. Oncol</italic>. <bold>42</bold>, 584&#8211;604 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.02225</pub-id><pub-id pub-id-type="pmid">38175972</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">NICE. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. (National Institute for Health and Care Excellence). Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/cg164/resources/familial-breast-cancer-classification-care-and-managing-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer-pdf-35109691767493">https://www.nice.org.uk/guidance/cg164/resources/familial-breast-cancer-classification-care-and-managing-breast-cancer-and-related-risks-in-people-with-a-family-history-of-breast-cancer-pdf-35109691767493</ext-link> (Accessed August 2024), 2023.<pub-id pub-id-type="pmid">31940157</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pujol</surname><given-names>P</given-names></name><etal/></person-group><article-title>Clinical practice guidelines for BRCA1 and BRCA2 genetic testing</article-title><source>Eur. J. Cancer</source><year>2021</year><volume>146</volume><fpage>30</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2020.12.023</pub-id><pub-id pub-id-type="pmid">33578357</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Pujol, P. et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <italic toggle="yes">Eur. J. Cancer</italic><bold>146</bold>, 30&#8211;47 (2021).<pub-id pub-id-type="pmid">33578357</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2020.12.023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kemp</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer</article-title><source>JAMA Netw. Open</source><year>2019</year><volume>2</volume><fpage>e194428</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.4428</pub-id><pub-id pub-id-type="pmid">31125106</pub-id><pub-id pub-id-type="pmcid">PMC6632150</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Kemp, Z. et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. <italic toggle="yes">JAMA Netw. Open</italic><bold>2</bold>, e194428 (2019).<pub-id pub-id-type="pmid">31125106</pub-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.4428</pub-id><pub-id pub-id-type="pmcid">PMC6632150</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberty-Oller</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Adherence to NCCN Guidelines for genetic testing in breast cancer patients: who are we missing?</article-title><source>Ann. Surg. Oncol.</source><year>2021</year><volume>28</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1245/s10434-020-09123-z</pub-id><pub-id pub-id-type="pmid">32918176</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Alberty-Oller, J. J. et al. Adherence to NCCN Guidelines for genetic testing in breast cancer patients: who are we missing? <italic toggle="yes">Ann. Surg. Oncol.</italic><bold>28</bold>, 281&#8211;286 (2021).<pub-id pub-id-type="pmid">32918176</pub-id><pub-id pub-id-type="doi">10.1245/s10434-020-09123-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>1409</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.02190</pub-id><pub-id pub-id-type="pmid">32125938</pub-id><pub-id pub-id-type="pmcid">PMC7193748</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Yadav, S. et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. <italic toggle="yes">J. Clin. Oncol.</italic><bold>38</bold>, 1409&#8211;1418 (2020).<pub-id pub-id-type="pmid">32125938</pub-id><pub-id pub-id-type="doi">10.1200/JCO.19.02190</pub-id><pub-id pub-id-type="pmcid">PMC7193748</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lux</surname><given-names>MP</given-names></name><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name></person-group><article-title>Breast cancer and genetic BRCA1/2 testing in routine clinical practice: why, when and for whom?</article-title><source>Geburtshilf. Frauenheilkd.</source><year>2023</year><volume>83</volume><fpage>310</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1055/a-1929-2629</pub-id><pub-id pub-id-type="pmcid">PMC9998182</pub-id><pub-id pub-id-type="pmid">36908286</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Lux, M. P. &amp; Fasching, P. A. Breast cancer and genetic BRCA1/2 testing in routine clinical practice: why, when and for whom? <italic toggle="yes">Geburtshilf. Frauenheilkd.</italic><bold>83</bold>, 310&#8211;320 (2023).<pub-id pub-id-type="doi">10.1055/a-1929-2629</pub-id><pub-id pub-id-type="pmcid">PMC9998182</pub-id><pub-id pub-id-type="pmid">36908286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manahan</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons</article-title><source>Ann. Surg. Oncol.</source><year>2019</year><volume>26</volume><fpage>3025</fpage><lpage>3031</lpage><pub-id pub-id-type="doi">10.1245/s10434-019-07549-8</pub-id><pub-id pub-id-type="pmid">31342359</pub-id><pub-id pub-id-type="pmcid">PMC6733830</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Manahan, E. R. et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. <italic toggle="yes">Ann. Surg. Oncol.</italic><bold>26</bold>, 3025&#8211;3031 (2019).<pub-id pub-id-type="pmid">31342359</pub-id><pub-id pub-id-type="doi">10.1245/s10434-019-07549-8</pub-id><pub-id pub-id-type="pmcid">PMC6733830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Childers</surname><given-names>CP</given-names></name><name name-style="western"><surname>Childers</surname><given-names>KK</given-names></name><name name-style="western"><surname>Maggard-Gibbons</surname><given-names>M</given-names></name><name name-style="western"><surname>Macinko</surname><given-names>J</given-names></name></person-group><article-title>National estimates of genetic testing in women with a history of breast or ovarian cancer</article-title><source>J. Clin. Oncol.</source><year>2017</year><volume>35</volume><fpage>3800</fpage><lpage>3806</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.73.6314</pub-id><pub-id pub-id-type="pmid">28820644</pub-id><pub-id pub-id-type="pmcid">PMC5707208</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Childers, C. P., Childers, K. K., Maggard-Gibbons, M. &amp; Macinko, J. National estimates of genetic testing in women with a history of breast or ovarian cancer. <italic toggle="yes">J. Clin. Oncol.</italic><bold>35</bold>, 3800&#8211;3806 (2017).<pub-id pub-id-type="pmid">28820644</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2017.73.6314</pub-id><pub-id pub-id-type="pmcid">PMC5707208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuffaha</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers</article-title><source>Genet. Med.</source><year>2018</year><volume>20</volume><fpage>985</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1038/gim.2017.231</pub-id><pub-id pub-id-type="pmid">29300376</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Tuffaha, H. W. et al. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. <italic toggle="yes">Genet. Med.</italic><bold>20</bold>, 985&#8211;994 (2018).<pub-id pub-id-type="pmid">29300376</pub-id><pub-id pub-id-type="doi">10.1038/gim.2017.231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Is BRCA mutation testing cost effective for early stage breast cancer patients compared to routine clinical surveillance? The case of an upper middle-income country in Asia</article-title><source>Appl. Health Econ. Health Policy</source><year>2018</year><volume>16</volume><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1007/s40258-018-0384-8</pub-id><pub-id pub-id-type="pmid">29572724</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Lim, K. K. et al. Is BRCA mutation testing cost effective for early stage breast cancer patients compared to routine clinical surveillance? The case of an upper middle-income country in Asia. <italic toggle="yes">Appl. Health Econ. Health Policy</italic><bold>16</bold>, 395&#8211;406 (2018).<pub-id pub-id-type="pmid">29572724</pub-id><pub-id pub-id-type="doi">10.1007/s40258-018-0384-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norum</surname><given-names>J</given-names></name><etal/></person-group><article-title>BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer</article-title><source>ESMO Open</source><year>2018</year><volume>3</volume><fpage>e000328</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2018-000328</pub-id><pub-id pub-id-type="pmid">29682331</pub-id><pub-id pub-id-type="pmcid">PMC5905828</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Norum, J. et al. BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. <italic toggle="yes">ESMO Open</italic><bold>3</bold>, e000328 (2018).<pub-id pub-id-type="pmid">29682331</pub-id><pub-id pub-id-type="doi">10.1136/esmoopen-2018-000328</pub-id><pub-id pub-id-type="pmcid">PMC5905828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><etal/></person-group><article-title>A cost-effectiveness analysis of multigene testing for all patients with breast cancer</article-title><source>JAMA Oncol.</source><year>2019</year><volume>5</volume><fpage>1718</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.3323</pub-id><pub-id pub-id-type="pmid">31580391</pub-id><pub-id pub-id-type="pmcid">PMC6777250</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Sun, L. et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. <italic toggle="yes">JAMA Oncol.</italic><bold>5</bold>, 1718&#8211;1730 (2019).<pub-id pub-id-type="pmid">31580391</pub-id><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.3323</pub-id><pub-id pub-id-type="pmcid">PMC6777250</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>HL</given-names></name><etal/></person-group><article-title>All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits</article-title><source>Br. J. Cancer</source><year>2023</year><volume>128</volume><fpage>638</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-02111-y</pub-id><pub-id pub-id-type="pmid">36564566</pub-id><pub-id pub-id-type="pmcid">PMC9938252</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Wu, H. L. et al. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits. <italic toggle="yes">Br. J. Cancer</italic><bold>128</bold>, 638&#8211;646 (2023).<pub-id pub-id-type="pmid">36564566</pub-id><pub-id pub-id-type="doi">10.1038/s41416-022-02111-y</pub-id><pub-id pub-id-type="pmcid">PMC9938252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beard</surname><given-names>C</given-names></name><name name-style="western"><surname>Monohan</surname><given-names>K</given-names></name><name name-style="western"><surname>Cicciarelli</surname><given-names>L</given-names></name><name name-style="western"><surname>James</surname><given-names>PA</given-names></name></person-group><article-title>Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre</article-title><source>Eur. J. Hum. Genet.</source><year>2021</year><volume>29</volume><fpage>872</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1038/s41431-021-00848-3</pub-id><pub-id pub-id-type="pmid">33723355</pub-id><pub-id pub-id-type="pmcid">PMC8111023</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Beard, C., Monohan, K., Cicciarelli, L. &amp; James, P. A. Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre. <italic toggle="yes">Eur. J. Hum. Genet.</italic><bold>29</bold>, 872&#8211;880 (2021).<pub-id pub-id-type="pmid">33723355</pub-id><pub-id pub-id-type="doi">10.1038/s41431-021-00848-3</pub-id><pub-id pub-id-type="pmcid">PMC8111023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abacan</surname><given-names>M</given-names></name><etal/></person-group><article-title>The global state of the genetic counseling profession</article-title><source>Eur. J. Hum. Genet.</source><year>2019</year><volume>27</volume><fpage>183</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/s41431-018-0252-x</pub-id><pub-id pub-id-type="pmid">30291341</pub-id><pub-id pub-id-type="pmcid">PMC6336871</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Abacan, M. et al. The global state of the genetic counseling profession. <italic toggle="yes">Eur. J. Hum. Genet.</italic><bold>27</bold>, 183&#8211;197 (2019).<pub-id pub-id-type="pmid">30291341</pub-id><pub-id pub-id-type="doi">10.1038/s41431-018-0252-x</pub-id><pub-id pub-id-type="pmcid">PMC6336871</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maiese</surname><given-names>DR</given-names></name><etal/></person-group><article-title>The 2019 medical genetics workforce: a focus on laboratory geneticists</article-title><source>Genet. Med.</source><year>2023</year><volume>25</volume><fpage>100834</fpage><pub-id pub-id-type="doi">10.1016/j.gim.2023.100834</pub-id><pub-id pub-id-type="pmid">36999554</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Maiese, D. R. et al. The 2019 medical genetics workforce: a focus on laboratory geneticists. <italic toggle="yes">Genet. Med.</italic><bold>25</bold>, 100834 (2023).<pub-id pub-id-type="pmid">36999554</pub-id><pub-id pub-id-type="doi">10.1016/j.gim.2023.100834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study</article-title><source>JAMA Oncol.</source><year>2015</year><volume>1</volume><fpage>1251</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.3048</pub-id><pub-id pub-id-type="pmid">26426480</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Armstrong, J. et al. Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study. <italic toggle="yes">JAMA Oncol.</italic><bold>1</bold>, 1251&#8211;1260 (2015).<pub-id pub-id-type="pmid">26426480</pub-id><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.3048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torr</surname><given-names>B</given-names></name><etal/></person-group><article-title>A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot</article-title><source>J. Med. Genet.</source><year>2022</year><volume>59</volume><fpage>1179</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1136/jmg-2022-108655</pub-id><pub-id pub-id-type="pmid">35868849</pub-id><pub-id pub-id-type="pmcid">PMC9691828</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Torr, B. et al. A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot. <italic toggle="yes">J. Med. Genet.</italic><bold>59</bold>, 1179&#8211;1188 (2022).<pub-id pub-id-type="pmid">35868849</pub-id><pub-id pub-id-type="doi">10.1136/jmg-2022-108655</pub-id><pub-id pub-id-type="pmcid">PMC9691828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delikurt</surname><given-names>T</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>GR</given-names></name><name name-style="western"><surname>Anastasiadou</surname><given-names>V</given-names></name><name name-style="western"><surname>Skirton</surname><given-names>H</given-names></name></person-group><article-title>A systematic review of factors that act as barriers to patient referral to genetic services</article-title><source>Eur. J. Hum. Genet.</source><year>2015</year><volume>23</volume><fpage>739</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2014.180</pub-id><pub-id pub-id-type="pmid">25205405</pub-id><pub-id pub-id-type="pmcid">PMC4795051</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Delikurt, T., Williamson, G. R., Anastasiadou, V. &amp; Skirton, H. A systematic review of factors that act as barriers to patient referral to genetic services. <italic toggle="yes">Eur. J. Hum. Genet.</italic><bold>23</bold>, 739&#8211;745 (2015).<pub-id pub-id-type="pmid">25205405</pub-id><pub-id pub-id-type="doi">10.1038/ejhg.2014.180</pub-id><pub-id pub-id-type="pmcid">PMC4795051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ormond</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Genetic counseling globally: where are we now?</article-title><source>Am. J. Med. Genet. C. Semin. Med. Genet.</source><year>2018</year><volume>178</volume><fpage>98</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1002/ajmg.c.31607</pub-id><pub-id pub-id-type="pmid">29575600</pub-id><pub-id pub-id-type="pmcid">PMC5947883</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Ormond, K. E. et al. Genetic counseling globally: where are we now? <italic toggle="yes">Am. J. Med. Genet. C. Semin. Med. Genet.</italic><bold>178</bold>, 98&#8211;107 (2018).<pub-id pub-id-type="pmid">29575600</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.c.31607</pub-id><pub-id pub-id-type="pmcid">PMC5947883</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shickh</surname><given-names>S</given-names></name><etal/></person-group><article-title>The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care</article-title><source>Genet. Med.</source><year>2021</year><volume>23</volume><fpage>1086</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/s41436-021-01112-1</pub-id><pub-id pub-id-type="pmid">33654192</pub-id><pub-id pub-id-type="pmcid">PMC9306004</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Shickh, S. et al. The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care. <italic toggle="yes">Genet. Med.</italic><bold>23</bold>, 1086&#8211;1094 (2021).<pub-id pub-id-type="pmid">33654192</pub-id><pub-id pub-id-type="doi">10.1038/s41436-021-01112-1</pub-id><pub-id pub-id-type="pmcid">PMC9306004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenberg</surname><given-names>SE</given-names></name><name name-style="western"><surname>Boothe</surname><given-names>E</given-names></name><name name-style="western"><surname>Delaney</surname><given-names>CL</given-names></name><name name-style="western"><surname>Noss</surname><given-names>R</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>SA</given-names></name></person-group><article-title>Genetic counseling service delivery models in the United States: assessment of changes in use from 2010 to 2017</article-title><source>J. Genet. Couns.</source><year>2020</year><volume>29</volume><fpage>1126</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1002/jgc4.1265</pub-id><pub-id pub-id-type="pmid">32314856</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Greenberg, S. E., Boothe, E., Delaney, C. L., Noss, R. &amp; Cohen, S. A. Genetic counseling service delivery models in the United States: assessment of changes in use from 2010 to 2017. <italic toggle="yes">J. Genet. Couns.</italic><bold>29</bold>, 1126&#8211;1141 (2020).<pub-id pub-id-type="pmid">32314856</pub-id><pub-id pub-id-type="doi">10.1002/jgc4.1265</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurian</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Genetic testing and counseling among patients with newly diagnosed breast cancer</article-title><source>JAMA</source><year>2017</year><volume>317</volume><fpage>531</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.16918</pub-id><pub-id pub-id-type="pmid">28170472</pub-id><pub-id pub-id-type="pmcid">PMC5530866</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Kurian, A. W. et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. <italic toggle="yes">JAMA</italic><bold>317</bold>, 531&#8211;534 (2017).<pub-id pub-id-type="pmid">28170472</pub-id><pub-id pub-id-type="doi">10.1001/jama.2016.16918</pub-id><pub-id pub-id-type="pmcid">PMC5530866</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>N</given-names></name><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>J</given-names></name><name name-style="western"><surname>Asgeirsson</surname><given-names>K</given-names></name><name name-style="western"><surname>Macmillan</surname><given-names>D</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>E</given-names></name></person-group><article-title>Changing practice: moving to a specialist nurse-led service for BRCA gene testing</article-title><source>Br. J. Nurs.</source><year>2020</year><volume>29</volume><fpage>S6</fpage><lpage>S13</lpage><pub-id pub-id-type="doi">10.12968/bjon.2020.29.10.S6</pub-id><pub-id pub-id-type="pmid">32463748</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Scott, N., O&#8217;Sullivan, J., Asgeirsson, K., Macmillan, D. &amp; Wilson, E. Changing practice: moving to a specialist nurse-led service for BRCA gene testing. <italic toggle="yes">Br. J. Nurs.</italic><bold>29</bold>, S6&#8211;S13 (2020).<pub-id pub-id-type="pmid">32463748</pub-id><pub-id pub-id-type="doi">10.12968/bjon.2020.29.10.S6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="other">Dusic, E. J. et al. Socioeconomic status and interest in genetic testing in a US-based sample. <italic toggle="yes">Healthcare</italic><bold>10</bold>, 880 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/healthcare10050880</pub-id><pub-id pub-id-type="pmcid">PMC9141316</pub-id><pub-id pub-id-type="pmid">35628017</pub-id></mixed-citation></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slomp</surname><given-names>C</given-names></name><etal/></person-group><article-title>The stepwise process of integrating a genetic counsellor into primary care</article-title><source>Eur. J. Hum. Genet.</source><year>2022</year><volume>30</volume><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1038/s41431-022-01040-x</pub-id><pub-id pub-id-type="pmid">35095102</pub-id><pub-id pub-id-type="pmcid">PMC8801315</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Slomp, C. et al. The stepwise process of integrating a genetic counsellor into primary care. <italic toggle="yes">Eur. J. Hum. Genet.</italic><bold>30</bold>, 772&#8211;781 (2022).<pub-id pub-id-type="pmid">35095102</pub-id><pub-id pub-id-type="doi">10.1038/s41431-022-01040-x</pub-id><pub-id pub-id-type="pmcid">PMC8801315</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Ricker</surname><given-names>C</given-names></name><name name-style="western"><surname>Stoffel</surname><given-names>EM</given-names></name><name name-style="western"><surname>Syngal</surname><given-names>S</given-names></name></person-group><article-title>Barriers and facilitators to genetic education, risk assessment, and testing: considerations on advancing equitable genetics care</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2023</year><volume>21</volume><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2022.10.025</pub-id><pub-id pub-id-type="pmid">36549838</pub-id><pub-id pub-id-type="pmcid">PMC10609510</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Rodriguez, N. J., Ricker, C., Stoffel, E. M. &amp; Syngal, S. Barriers and facilitators to genetic education, risk assessment, and testing: considerations on advancing equitable genetics care. <italic toggle="yes">Clin. Gastroenterol. Hepatol.</italic><bold>21</bold>, 3&#8211;7 (2023).<pub-id pub-id-type="pmid">36549838</pub-id><pub-id pub-id-type="doi">10.1016/j.cgh.2022.10.025</pub-id><pub-id pub-id-type="pmcid">PMC10609510</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapman-Davis</surname><given-names>E</given-names></name><etal/></person-group><article-title>Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center</article-title><source>J. Gen. Intern. Med.</source><year>2021</year><volume>36</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/s11606-020-06064-x</pub-id><pub-id pub-id-type="pmid">32720237</pub-id><pub-id pub-id-type="pmcid">PMC7859010</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Chapman-Davis, E. et al. Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center. <italic toggle="yes">J. Gen. Intern. Med.</italic><bold>36</bold>, 35&#8211;42 (2021).<pub-id pub-id-type="pmid">32720237</pub-id><pub-id pub-id-type="doi">10.1007/s11606-020-06064-x</pub-id><pub-id pub-id-type="pmcid">PMC7859010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Racial disparities in breast cancer hereditary risk assessment referrals</article-title><source>J. Genet. Couns.</source><year>2020</year><volume>29</volume><fpage>587</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1002/jgc4.1250</pub-id><pub-id pub-id-type="pmid">32196827</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Peterson, J. M. et al. Racial disparities in breast cancer hereditary risk assessment referrals. <italic toggle="yes">J. Genet. Couns.</italic><bold>29</bold>, 587&#8211;593 (2020).<pub-id pub-id-type="pmid">32196827</pub-id><pub-id pub-id-type="doi">10.1002/jgc4.1250</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cragun</surname><given-names>D</given-names></name><etal/></person-group><article-title>Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors</article-title><source>Cancer</source><year>2017</year><volume>123</volume><fpage>2497</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1002/cncr.30621</pub-id><pub-id pub-id-type="pmid">28182268</pub-id><pub-id pub-id-type="pmcid">PMC5474124</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Cragun, D. et al. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. <italic toggle="yes">Cancer</italic><bold>123</bold>, 2497&#8211;2505 (2017).<pub-id pub-id-type="pmid">28182268</pub-id><pub-id pub-id-type="doi">10.1002/cncr.30621</pub-id><pub-id pub-id-type="pmcid">PMC5474124</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hann</surname><given-names>KEJ</given-names></name><etal/></person-group><article-title>Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review</article-title><source>BMC Public Health</source><year>2017</year><volume>17</volume><fpage>503</fpage><pub-id pub-id-type="doi">10.1186/s12889-017-4375-8</pub-id><pub-id pub-id-type="pmid">28545429</pub-id><pub-id pub-id-type="pmcid">PMC5445407</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Hann, K. E. J. et al. Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review. <italic toggle="yes">BMC Public Health</italic><bold>17</bold>, 503 (2017).<pub-id pub-id-type="pmid">28545429</pub-id><pub-id pub-id-type="doi">10.1186/s12889-017-4375-8</pub-id><pub-id pub-id-type="pmcid">PMC5445407</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatineni</surname><given-names>S</given-names></name><etal/></person-group><article-title>Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center</article-title><source>Cancer Med.</source><year>2022</year><volume>11</volume><fpage>1465</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1002/cam4.4541</pub-id><pub-id pub-id-type="pmid">35040284</pub-id><pub-id pub-id-type="pmcid">PMC8921894</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Tatineni, S. et al. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center. <italic toggle="yes">Cancer Med.</italic><bold>11</bold>, 1465&#8211;1473 (2022).<pub-id pub-id-type="pmid">35040284</pub-id><pub-id pub-id-type="doi">10.1002/cam4.4541</pub-id><pub-id pub-id-type="pmcid">PMC8921894</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caswell-Jin</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk</article-title><source>Genet. Med.</source><year>2018</year><volume>20</volume><fpage>234</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/gim.2017.96</pub-id><pub-id pub-id-type="pmid">28749474</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Caswell-Jin, J. L. et al. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. <italic toggle="yes">Genet. Med.</italic><bold>20</bold>, 234&#8211;239 (2018).<pub-id pub-id-type="pmid">28749474</pub-id><pub-id pub-id-type="doi">10.1038/gim.2017.96</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>T</given-names></name><etal/></person-group><article-title>Racial and ethnic differences in BRCA1/2 and multigene panel testing among young breast cancer patients</article-title><source>J. Cancer Educ.</source><year>2021</year><volume>36</volume><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1007/s13187-019-01646-8</pub-id><pub-id pub-id-type="pmid">31802423</pub-id><pub-id pub-id-type="pmcid">PMC7293107</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Jones, T. et al. Racial and ethnic differences in BRCA1/2 and multigene panel testing among young breast cancer patients. <italic toggle="yes">J. Cancer Educ.</italic><bold>36</bold>, 463&#8211;469 (2021).<pub-id pub-id-type="pmid">31802423</pub-id><pub-id pub-id-type="doi">10.1007/s13187-019-01646-8</pub-id><pub-id pub-id-type="pmcid">PMC7293107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landry</surname><given-names>LG</given-names></name><name name-style="western"><surname>Ali</surname><given-names>N</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DR</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>HL</given-names></name><name name-style="western"><surname>Bonham</surname><given-names>VL</given-names></name></person-group><article-title>Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice</article-title><source>Health Aff.</source><year>2018</year><volume>37</volume><fpage>780</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.2017.1595</pub-id><pub-id pub-id-type="pmid">29733732</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Landry, L. G., Ali, N., Williams, D. R., Rehm, H. L. &amp; Bonham, V. L. Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice. <italic toggle="yes">Health Aff.</italic><bold>37</bold>, 780&#8211;785 (2018).<pub-id pub-id-type="doi">10.1377/hlthaff.2017.1595</pub-id><pub-id pub-id-type="pmid">29733732</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>DG</given-names></name><etal/></person-group><article-title>The importance of ethnicity: are breast cancer polygenic risk scores ready for women who are not of White European origin?</article-title><source>Int. J. Cancer</source><year>2022</year><volume>150</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1002/ijc.33782</pub-id><pub-id pub-id-type="pmid">34460111</pub-id><pub-id pub-id-type="pmcid">PMC9290473</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Evans, D. G. et al. The importance of ethnicity: are breast cancer polygenic risk scores ready for women who are not of White European origin? <italic toggle="yes">Int. J. Cancer</italic><bold>150</bold>, 73&#8211;79 (2022).<pub-id pub-id-type="pmid">34460111</pub-id><pub-id pub-id-type="doi">10.1002/ijc.33782</pub-id><pub-id pub-id-type="pmcid">PMC9290473</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuster</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Priorities to promote participant engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network</article-title><source>Cancer Epidemiol. Biomarers</source><year>2023</year><volume>32</volume><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-22-0356</pub-id><pub-id pub-id-type="pmcid">PMC10068438</pub-id><pub-id pub-id-type="pmid">36791345</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Schuster, A. L. et al. Priorities to promote participant engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. <italic toggle="yes">Cancer Epidemiol. Biomarers</italic><bold>32</bold>, 487&#8211;495 (2023).<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-22-0356</pub-id><pub-id pub-id-type="pmcid">PMC10068438</pub-id><pub-id pub-id-type="pmid">36791345</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canedo</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Barriers and facilitators to dissemination and adoption of precision medicine among Hispanics/Latinos</article-title><source>BMC Public Health</source><year>2020</year><volume>20</volume><fpage>603</fpage><pub-id pub-id-type="doi">10.1186/s12889-020-08718-1</pub-id><pub-id pub-id-type="pmid">32357943</pub-id><pub-id pub-id-type="pmcid">PMC7195743</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Canedo, J. R. et al. Barriers and facilitators to dissemination and adoption of precision medicine among Hispanics/Latinos. <italic toggle="yes">BMC Public Health</italic><bold>20</bold>, 603 (2020).<pub-id pub-id-type="pmid">32357943</pub-id><pub-id pub-id-type="doi">10.1186/s12889-020-08718-1</pub-id><pub-id pub-id-type="pmcid">PMC7195743</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>A</given-names></name><etal/></person-group><article-title>Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>29506</fpage><pub-id pub-id-type="doi">10.1038/srep29506</pub-id><pub-id pub-id-type="pmid">27406733</pub-id><pub-id pub-id-type="pmcid">PMC4942815</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">George, A. et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. <italic toggle="yes">Sci. Rep.</italic><bold>6</bold>, 29506 (2016).<pub-id pub-id-type="pmid">27406733</pub-id><pub-id pub-id-type="doi">10.1038/srep29506</pub-id><pub-id pub-id-type="pmcid">PMC4942815</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><mixed-citation publication-type="other">Bokkers, K. et al. The feasibility of implementing mainstream germline genetic testing in routine cancer care-a systematic review. <italic toggle="yes">Cancers</italic><bold>14</bold>, 1059 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14041059</pub-id><pub-id pub-id-type="pmcid">PMC8870548</pub-id><pub-id pub-id-type="pmid">35205807</pub-id></mixed-citation></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ip</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer</article-title><source>Asia Pac. J. Clin. Oncol.</source><year>2022</year><volume>18</volume><fpage>e414</fpage><lpage>e419</lpage><pub-id pub-id-type="doi">10.1111/ajco.13741</pub-id><pub-id pub-id-type="pmid">35098668</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Ip, E. et al. Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer. <italic toggle="yes">Asia Pac. J. Clin. Oncol.</italic><bold>18</bold>, e414&#8211;e419 (2022).<pub-id pub-id-type="pmid">35098668</pub-id><pub-id pub-id-type="doi">10.1111/ajco.13741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bokkers</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective</article-title><source>Gynecol. Oncol.</source><year>2022</year><volume>167</volume><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2022.08.011</pub-id><pub-id pub-id-type="pmid">36031452</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Bokkers, K. et al. Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective. <italic toggle="yes">Gynecol. Oncol.</italic><bold>167</bold>, 115&#8211;122 (2022).<pub-id pub-id-type="pmid">36031452</pub-id><pub-id pub-id-type="doi">10.1016/j.ygyno.2022.08.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bokkers</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing</article-title><source>Hered. Cancer Clin. Pract.</source><year>2022</year><volume>20</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s13053-022-00238-w</pub-id><pub-id pub-id-type="pmid">36076240</pub-id><pub-id pub-id-type="pmcid">PMC9461259</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Bokkers, K. et al. Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing. <italic toggle="yes">Hered. Cancer Clin. Pract.</italic><bold>20</bold>, 33 (2022).<pub-id pub-id-type="pmid">36076240</pub-id><pub-id pub-id-type="doi">10.1186/s13053-022-00238-w</pub-id><pub-id pub-id-type="pmcid">PMC9461259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="other">Richardson, M. et al. Oncology clinic-based hereditary cancer genetic testing in a population-based health care system. <italic toggle="yes">Cancers</italic><bold>12</bold>, 338 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12020338</pub-id><pub-id pub-id-type="pmcid">PMC7072228</pub-id><pub-id pub-id-type="pmid">32028617</pub-id></mixed-citation></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piedimonte</surname><given-names>S</given-names></name><etal/></person-group><article-title>BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral</article-title><source>Int. J. Gynecol. Cancer</source><year>2020</year><volume>30</volume><fpage>1757</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1136/ijgc-2020-001261</pub-id><pub-id pub-id-type="pmid">32759180</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Piedimonte, S. et al. BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral. <italic toggle="yes">Int. J. Gynecol. Cancer</italic><bold>30</bold>, 1757&#8211;1761 (2020).<pub-id pub-id-type="pmid">32759180</pub-id><pub-id pub-id-type="doi">10.1136/ijgc-2020-001261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rumford</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oncologist-led BRCA &#8216;mainstreaming&#8217; in the ovarian cancer clinic: a study of 255 patients and its impact on their management</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>3390</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-60149-5</pub-id><pub-id pub-id-type="pmid">32098980</pub-id><pub-id pub-id-type="pmcid">PMC7042365</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Rumford, M. et al. Oncologist-led BRCA &#8216;mainstreaming&#8217; in the ovarian cancer clinic: a study of 255 patients and its impact on their management. <italic toggle="yes">Sci. Rep.</italic><bold>10</bold>, 3390 (2020).<pub-id pub-id-type="pmid">32098980</pub-id><pub-id pub-id-type="doi">10.1038/s41598-020-60149-5</pub-id><pub-id pub-id-type="pmcid">PMC7042365</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">Lapointe, J. et al. A collaborative model to implement flexible, accessible and efficient oncogenetic services for hereditary breast and ovarian cancer: the C-MOnGene study. <italic toggle="yes">Cancers</italic><bold>13</bold>, 2729 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13112729</pub-id><pub-id pub-id-type="pmcid">PMC8198545</pub-id><pub-id pub-id-type="pmid">34072979</pub-id></mixed-citation></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hallowell</surname><given-names>N</given-names></name><etal/></person-group><article-title>Moving into the mainstream: healthcare professionals&#8217; views of implementing treatment focussed genetic testing in breast cancer care</article-title><source>Fam. Cancer</source><year>2019</year><volume>18</volume><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1007/s10689-019-00122-y</pub-id><pub-id pub-id-type="pmid">30689103</pub-id><pub-id pub-id-type="pmcid">PMC6560008</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Hallowell, N. et al. Moving into the mainstream: healthcare professionals&#8217; views of implementing treatment focussed genetic testing in breast cancer care. <italic toggle="yes">Fam. Cancer</italic><bold>18</bold>, 293&#8211;301 (2019).<pub-id pub-id-type="pmid">30689103</pub-id><pub-id pub-id-type="doi">10.1007/s10689-019-00122-y</pub-id><pub-id pub-id-type="pmcid">PMC6560008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isselhard</surname><given-names>A</given-names></name><etal/></person-group><article-title>Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study</article-title><source>Trials</source><year>2020</year><volume>21</volume><fpage>501</fpage><pub-id pub-id-type="doi">10.1186/s13063-020-04431-x</pub-id><pub-id pub-id-type="pmid">32513307</pub-id><pub-id pub-id-type="pmcid">PMC7278068</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Isselhard, A. et al. Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study. <italic toggle="yes">Trials</italic><bold>21</bold>, 501 (2020).<pub-id pub-id-type="pmid">32513307</pub-id><pub-id pub-id-type="doi">10.1186/s13063-020-04431-x</pub-id><pub-id pub-id-type="pmcid">PMC7278068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger-Hoger</surname><given-names>B</given-names></name><etal/></person-group><article-title>Nurse-led decision coaching by specialized nurses for healthy BRCA1/2 gene mutation carriers - adaptation and pilot testing of a curriculum for nurses: a qualitative study</article-title><source>BMC Nurs.</source><year>2022</year><volume>21</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s12912-022-00810-8</pub-id><pub-id pub-id-type="pmid">35139834</pub-id><pub-id pub-id-type="pmcid">PMC8829999</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Berger-Hoger, B. et al. Nurse-led decision coaching by specialized nurses for healthy BRCA1/2 gene mutation carriers - adaptation and pilot testing of a curriculum for nurses: a qualitative study. <italic toggle="yes">BMC Nurs.</italic><bold>21</bold>, 42 (2022).<pub-id pub-id-type="pmid">35139834</pub-id><pub-id pub-id-type="doi">10.1186/s12912-022-00810-8</pub-id><pub-id pub-id-type="pmcid">PMC8829999</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>S</given-names></name><etal/></person-group><article-title>Patients&#8217; views of Treatment-Focused Genetic Testing (TFGT): some lessons for the mainstreaming of BRCA1 and BRCA2 testing</article-title><source>J. Genet. Couns.</source><year>2018</year><volume>27</volume><fpage>1459</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1007/s10897-018-0261-5</pub-id><pub-id pub-id-type="pmid">29752676</pub-id><pub-id pub-id-type="pmcid">PMC6209051</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Wright, S. et al. Patients&#8217; views of Treatment-Focused Genetic Testing (TFGT): some lessons for the mainstreaming of BRCA1 and BRCA2 testing. <italic toggle="yes">J. Genet. Couns.</italic><bold>27</bold>, 1459&#8211;1472 (2018).<pub-id pub-id-type="pmid">29752676</pub-id><pub-id pub-id-type="doi">10.1007/s10897-018-0261-5</pub-id><pub-id pub-id-type="pmcid">PMC6209051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nilsson</surname><given-names>MP</given-names></name><etal/></person-group><article-title>High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study</article-title><source>Breast Cancer Res. Treat.</source><year>2019</year><volume>173</volume><fpage>313</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1007/s10549-018-5000-y</pub-id><pub-id pub-id-type="pmid">30311024</pub-id><pub-id pub-id-type="pmcid">PMC6394590</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Nilsson, M. P. et al. High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study. <italic toggle="yes">Breast Cancer Res. Treat.</italic><bold>173</bold>, 313&#8211;318 (2019).<pub-id pub-id-type="pmid">30311024</pub-id><pub-id pub-id-type="doi">10.1007/s10549-018-5000-y</pub-id><pub-id pub-id-type="pmcid">PMC6394590</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleeson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing</article-title><source>Oncol. Nurs. Forum</source><year>2013</year><volume>40</volume><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1188/13.ONF.40-03AP</pub-id><pub-id pub-id-type="pmid">23619104</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Gleeson, M. et al. Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing. <italic toggle="yes">Oncol. Nurs. Forum</italic><bold>40</bold>, 275&#8211;283 (2013).<pub-id pub-id-type="pmid">23619104</pub-id><pub-id pub-id-type="doi">10.1188/13.ONF.40-03AP</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoberg-Vetti</surname><given-names>H</given-names></name><etal/></person-group><article-title>BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study</article-title><source>Eur. J. Hum. Genet.</source><year>2016</year><volume>24</volume><fpage>881</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2015.196</pub-id><pub-id pub-id-type="pmid">26350514</pub-id><pub-id pub-id-type="pmcid">PMC4867439</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Hoberg-Vetti, H. et al. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. <italic toggle="yes">Eur. J. Hum. Genet.</italic><bold>24</bold>, 881&#8211;888 (2016).<pub-id pub-id-type="pmid">26350514</pub-id><pub-id pub-id-type="doi">10.1038/ejhg.2015.196</pub-id><pub-id pub-id-type="pmcid">PMC4867439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cragun</surname><given-names>D</given-names></name><etal/></person-group><article-title>Differences in BRCA counseling and testing practices based on ordering provider type</article-title><source>Genet. Med.</source><year>2015</year><volume>17</volume><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/gim.2014.75</pub-id><pub-id pub-id-type="pmid">24922460</pub-id><pub-id pub-id-type="pmcid">PMC4264999</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Cragun, D. et al. Differences in BRCA counseling and testing practices based on ordering provider type. <italic toggle="yes">Genet. Med.</italic><bold>17</bold>, 51&#8211;57 (2015).<pub-id pub-id-type="pmid">24922460</pub-id><pub-id pub-id-type="doi">10.1038/gim.2014.75</pub-id><pub-id pub-id-type="pmcid">PMC4264999</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fallowfield</surname><given-names>L</given-names></name><etal/></person-group><article-title>Talking about Risk, Uncertainties of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 &amp; BRCA2 testing</article-title><source>Br. J. Cancer</source><year>2022</year><volume>127</volume><fpage>1116</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-01871-x</pub-id><pub-id pub-id-type="pmid">35715636</pub-id><pub-id pub-id-type="pmcid">PMC9470577</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Fallowfield, L. et al. Talking about Risk, Uncertainties of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 &amp; BRCA2 testing. <italic toggle="yes">Br. J. Cancer</italic><bold>127</bold>, 1116&#8211;1122 (2022).<pub-id pub-id-type="pmid">35715636</pub-id><pub-id pub-id-type="doi">10.1038/s41416-022-01871-x</pub-id><pub-id pub-id-type="pmcid">PMC9470577</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>W</given-names></name><etal/></person-group><article-title>Patient-facing digital tools for delivering genetic services: a systematic review</article-title><source>J. Med. Genet.</source><year>2023</year><volume>60</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1136/jmg-2022-108653</pub-id><pub-id pub-id-type="pmid">36137613</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Lee, W. et al. Patient-facing digital tools for delivering genetic services: a systematic review. <italic toggle="yes">J. Med. Genet.</italic><bold>60</bold>, 1&#8211;10 (2023).<pub-id pub-id-type="pmid">36137613</pub-id><pub-id pub-id-type="doi">10.1136/jmg-2022-108653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bombard</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hayeems</surname><given-names>RZ</given-names></name></person-group><article-title>How digital tools can advance quality and equity in genomic medicine</article-title><source>Nat. Rev. Genet.</source><year>2020</year><volume>21</volume><fpage>505</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/s41576-020-0260-x</pub-id><pub-id pub-id-type="pmid">32601319</pub-id><pub-id pub-id-type="pmcid">PMC7322700</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Bombard, Y. &amp; Hayeems, R. Z. How digital tools can advance quality and equity in genomic medicine. <italic toggle="yes">Nat. Rev. Genet.</italic><bold>21</bold>, 505&#8211;506 (2020).<pub-id pub-id-type="pmid">32601319</pub-id><pub-id pub-id-type="doi">10.1038/s41576-020-0260-x</pub-id><pub-id pub-id-type="pmcid">PMC7322700</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torr</surname><given-names>B</given-names></name><etal/></person-group><article-title>LBA101 BRCA-DIRECT: a randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer</article-title><source>Ann. Oncol.</source><year>2023</year><volume>34</volume><fpage>S1339</fpage><pub-id pub-id-type="doi">10.1016/j.annonc.2023.10.105</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Torr, B. et al. LBA101 BRCA-DIRECT: a randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer. <italic toggle="yes">Ann. Oncol.</italic><bold>34</bold>, S1339 (2023).<pub-id pub-id-type="doi">10.1016/j.annonc.2023.10.105</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Olaparib use in patients with metastatic breast cancer harboring somatic BRCA1/2 mutations or mutations in non-BRCA1/2, DNA damage repair genes</article-title><source>Clin. Breast Cancer</source><year>2022</year><volume>22</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.clbc.2021.12.007</pub-id><pub-id pub-id-type="pmid">35074264</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Walsh, E. M. et al. Olaparib use in patients with metastatic breast cancer harboring somatic BRCA1/2 mutations or mutations in non-BRCA1/2, DNA damage repair genes. <italic toggle="yes">Clin. Breast Cancer</italic><bold>22</bold>, 319&#8211;325 (2022).<pub-id pub-id-type="pmid">35074264</pub-id><pub-id pub-id-type="doi">10.1016/j.clbc.2021.12.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tung</surname><given-names>NM</given-names></name><etal/></person-group><article-title>TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>4274</fpage><lpage>4282</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.02151</pub-id><pub-id pub-id-type="pmid">33119476</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Tung, N. M. et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. <italic toggle="yes">J. Clin. Oncol.</italic><bold>38</bold>, 4274&#8211;4282 (2020).<pub-id pub-id-type="pmid">33119476</pub-id><pub-id pub-id-type="doi">10.1200/JCO.20.02151</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batalini</surname><given-names>F</given-names></name><etal/></person-group><article-title>Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi)</article-title><source>J. Clin. Oncol.</source><year>2021</year><volume>39</volume><fpage>10512</fpage><lpage>10512</lpage><pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.10512</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Batalini, F. et al. Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi). <italic toggle="yes">J. Clin. Oncol.</italic><bold>39</bold>, 10512&#8211;10512 (2021).<pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.10512</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial</article-title><source>Gynecol. Oncol.</source><year>2021</year><volume>163</volume><fpage>563</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2021.10.002</pub-id><pub-id pub-id-type="pmid">34742578</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Hodgson, D. R. et al. Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial. <italic toggle="yes">Gynecol. Oncol.</italic><bold>163</bold>, 563&#8211;568 (2021).<pub-id pub-id-type="pmid">34742578</pub-id><pub-id pub-id-type="doi">10.1016/j.ygyno.2021.10.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Determinants of response to talazoparib in patients with HER2-negative, germline BRCA1/2-mutated breast cancer</article-title><source>Clin. Cancer Res.</source><year>2022</year><volume>28</volume><fpage>1383</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-2080</pub-id><pub-id pub-id-type="pmid">35091441</pub-id><pub-id pub-id-type="pmcid">PMC9365365</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Blum, J. L. et al. Determinants of response to talazoparib in patients with HER2-negative, germline BRCA1/2-mutated breast cancer. <italic toggle="yes">Clin. Cancer Res.</italic><bold>28</bold>, 1383&#8211;1390 (2022).<pub-id pub-id-type="pmid">35091441</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-2080</pub-id><pub-id pub-id-type="pmcid">PMC9365365</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><mixed-citation publication-type="other">Bekos, C. et al. Reliability of tumor testing compared to germline testing for detecting BRCA1 and BRCA2 mutations in patients with epithelial ovarian cancer. <italic toggle="yes">J. Pers. Med.</italic><bold>11</bold>, 593 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm11070593</pub-id><pub-id pub-id-type="pmcid">PMC8305542</pub-id><pub-id pub-id-type="pmid">34202525</pub-id></mixed-citation></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callens</surname><given-names>C</given-names></name><etal/></person-group><article-title>Concordance between tumor and germline BRCA status in high-grade ovarian carcinoma patients in the phase III PAOLA-1/ENGOT-ov25 trial</article-title><source>J. Natl Cancer Inst.</source><year>2021</year><volume>113</volume><fpage>917</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1093/jnci/djaa193</pub-id><pub-id pub-id-type="pmid">33372675</pub-id><pub-id pub-id-type="pmcid">PMC8246800</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Callens, C. et al. Concordance between tumor and germline BRCA status in high-grade ovarian carcinoma patients in the phase III PAOLA-1/ENGOT-ov25 trial. <italic toggle="yes">J. Natl Cancer Inst.</italic><bold>113</bold>, 917&#8211;923 (2021).<pub-id pub-id-type="pmid">33372675</pub-id><pub-id pub-id-type="doi">10.1093/jnci/djaa193</pub-id><pub-id pub-id-type="pmcid">PMC8246800</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD</article-title><source>Ann. Oncol.</source><year>2021</year><volume>32</volume><fpage>1582</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.08.2154</pub-id><pub-id pub-id-type="pmid">34500047</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Hodgson, D. et al. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. <italic toggle="yes">Ann. Oncol.</italic><bold>32</bold>, 1582&#8211;1589 (2021).<pub-id pub-id-type="pmid">34500047</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2021.08.2154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivera</surname><given-names>D</given-names></name><etal/></person-group><article-title>Implementing NGS-based BRCA tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations</article-title><source>J. Clin. Pathol.</source><year>2021</year><volume>74</volume><fpage>596</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2020-206840</pub-id><pub-id pub-id-type="pmid">32895300</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Rivera, D. et al. Implementing NGS-based BRCA tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations. <italic toggle="yes">J. Clin. Pathol.</italic><bold>74</bold>, 596&#8211;603 (2021).<pub-id pub-id-type="pmid">32895300</pub-id><pub-id pub-id-type="doi">10.1136/jclinpath-2020-206840</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polak</surname><given-names>P</given-names></name><etal/></person-group><article-title>A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer</article-title><source>Nat. Genet.</source><year>2017</year><volume>49</volume><fpage>1476</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1038/ng.3934</pub-id><pub-id pub-id-type="pmid">28825726</pub-id><pub-id pub-id-type="pmcid">PMC7376751</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Polak, P. et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. <italic toggle="yes">Nat. Genet.</italic><bold>49</bold>, 1476&#8211;1486 (2017).<pub-id pub-id-type="pmid">28825726</pub-id><pub-id pub-id-type="doi">10.1038/ng.3934</pub-id><pub-id pub-id-type="pmcid">PMC7376751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/s12885-021-09082-y</pub-id><pub-id pub-id-type="pmid">34979999</pub-id><pub-id pub-id-type="pmcid">PMC8722117</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Lai, Z. et al. Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. <italic toggle="yes">BMC Cancer</italic><bold>22</bold>, 13 (2022).<pub-id pub-id-type="pmid">34979999</pub-id><pub-id pub-id-type="doi">10.1186/s12885-021-09082-y</pub-id><pub-id pub-id-type="pmcid">PMC8722117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zehir</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1038/nm.4333</pub-id><pub-id pub-id-type="pmid">28481359</pub-id><pub-id pub-id-type="pmcid">PMC5461196</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <italic toggle="yes">Nat. Med.</italic><bold>23</bold>, 703&#8211;713 (2017).<pub-id pub-id-type="pmid">28481359</pub-id><pub-id pub-id-type="doi">10.1038/nm.4333</pub-id><pub-id pub-id-type="pmcid">PMC5461196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><mixed-citation publication-type="other">US Food and Drug Administration. Alpelisib in combination with fulvestrant for the treatment of PIK3CA-mutated, advanced or metastatic breast cancer - approval letter. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212526Orig1s000Approv.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212526Orig1s000Approv.pdf</ext-link> (Accessed August 2024), 2019.</mixed-citation></ref><ref id="CR125"><label>125.</label><mixed-citation publication-type="other">US Food and Drug Administration. Capivasertib in combination with fulvestrant for the treatment of advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration - approval letter. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/218197Orig1s000ltr.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/218197Orig1s000ltr.pdf</ext-link> (Accessed August 2024), 2023.</mixed-citation></ref><ref id="CR126"><label>126.</label><mixed-citation publication-type="other">US Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors</ext-link> (Accessed August 2024), 2020.</mixed-citation></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>YL</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>ZK</given-names></name></person-group><article-title>The future of parallel tumor and germline genetic testing: is there a role for all patients with cancer?</article-title><source>J. Natl Compr. Cancer Netw.</source><year>2021</year><volume>19</volume><fpage>871</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2021.7044</pub-id><pub-id pub-id-type="pmcid">PMC11123333</pub-id><pub-id pub-id-type="pmid">34340209</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Liu, Y. L. &amp; Stadler, Z. K. The future of parallel tumor and germline genetic testing: is there a role for all patients with cancer? <italic toggle="yes">J. Natl Compr. Cancer Netw.</italic><bold>19</bold>, 871&#8211;878 (2021).<pub-id pub-id-type="doi">10.6004/jnccn.2021.7044</pub-id><pub-id pub-id-type="pmcid">PMC11123333</pub-id><pub-id pub-id-type="pmid">34340209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Concordance between genomic alterations detected by tumor and germline sequencing: results from a tertiary care academic center molecular tumor board</article-title><source>Oncologist</source><year>2023</year><volume>28</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyac164</pub-id><pub-id pub-id-type="pmid">35962742</pub-id><pub-id pub-id-type="pmcid">PMC9847540</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Green, M. F. et al. Concordance between genomic alterations detected by tumor and germline sequencing: results from a tertiary care academic center molecular tumor board. <italic toggle="yes">Oncologist</italic><bold>28</bold>, 33&#8211;39 (2023).<pub-id pub-id-type="pmid">35962742</pub-id><pub-id pub-id-type="doi">10.1093/oncolo/oyac164</pub-id><pub-id pub-id-type="pmcid">PMC9847540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slavin</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>JCO1800328</fpage><pub-id pub-id-type="doi">10.1200/JCO.18.00328</pub-id><pub-id pub-id-type="pmid">30339520</pub-id><pub-id pub-id-type="pmcid">PMC6286162</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Slavin, T. P. et al. Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing. <italic toggle="yes">J. Clin. Oncol.</italic><bold>36</bold>, JCO1800328 (2018).<pub-id pub-id-type="pmid">30339520</pub-id><pub-id pub-id-type="doi">10.1200/JCO.18.00328</pub-id><pub-id pub-id-type="pmcid">PMC6286162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anaclerio</surname><given-names>F</given-names></name><etal/></person-group><article-title>Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis</article-title><source>Front. Genet.</source><year>2023</year><volume>14</volume><fpage>1060504</fpage><pub-id pub-id-type="doi">10.3389/fgene.2023.1060504</pub-id><pub-id pub-id-type="pmid">37065479</pub-id><pub-id pub-id-type="pmcid">PMC10104445</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Anaclerio, F. et al. Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis. <italic toggle="yes">Front. Genet.</italic><bold>14</bold>, 1060504 (2023).<pub-id pub-id-type="pmid">37065479</pub-id><pub-id pub-id-type="doi">10.3389/fgene.2023.1060504</pub-id><pub-id pub-id-type="pmcid">PMC10104445</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comeaux</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes</article-title><source>Mol. Genet. Genom. Med.</source><year>2022</year><volume>10</volume><fpage>e2031</fpage><pub-id pub-id-type="doi">10.1002/mgg3.2031</pub-id><pub-id pub-id-type="pmcid">PMC9544212</pub-id><pub-id pub-id-type="pmid">36054727</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Comeaux, J. G. et al. Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes. <italic toggle="yes">Mol. Genet. Genom. Med.</italic><bold>10</bold>, e2031 (2022).<pub-id pub-id-type="doi">10.1002/mgg3.2031</pub-id><pub-id pub-id-type="pmcid">PMC9544212</pub-id><pub-id pub-id-type="pmid">36054727</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><mixed-citation publication-type="other">Breast Cancer Association, Consortium et al. Breast cancer risk genes - association analysis in more than 113,000 women. N. Engl. J.Med. <bold>384</bold>, 428&#8211;439 (2021)..<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1913948</pub-id><pub-id pub-id-type="pmcid">PMC7611105</pub-id><pub-id pub-id-type="pmid">33471991</pub-id></mixed-citation></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruber</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes</article-title><source>Nat. Cancer</source><year>2022</year><volume>3</volume><fpage>1181</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00439-1</pub-id><pub-id pub-id-type="pmid">36253484</pub-id><pub-id pub-id-type="pmcid">PMC9586861</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Gruber, J. J. et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. <italic toggle="yes">Nat. Cancer</italic><bold>3</bold>, 1181&#8211;1191 (2022).<pub-id pub-id-type="pmid">36253484</pub-id><pub-id pub-id-type="doi">10.1038/s43018-022-00439-1</pub-id><pub-id pub-id-type="pmcid">PMC9586861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eikesdal</surname><given-names>HP</given-names></name><etal/></person-group><article-title>Olaparib monotherapy as primary treatment in unselected triple negative breast cancer</article-title><source>Ann. Oncol.</source><year>2021</year><volume>32</volume><fpage>240</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.11.009</pub-id><pub-id pub-id-type="pmid">33242536</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Eikesdal, H. P. et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. <italic toggle="yes">Ann. Oncol.</italic><bold>32</bold>, 240&#8211;249 (2021).<pub-id pub-id-type="pmid">33242536</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2020.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><mixed-citation publication-type="other">Tsoulaki, O. et al. Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice. <italic toggle="yes">Br. J. Cancer</italic><bold>130</bold>, 2027&#8211;2036 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-024-02733-4</pub-id><pub-id pub-id-type="pmcid">PMC11183136</pub-id><pub-id pub-id-type="pmid">38834743</pub-id></mixed-citation></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carver</surname><given-names>T</given-names></name><etal/></person-group><article-title>CanRisk tool-A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants</article-title><source>Cancer Epidemiol. Biomarkers Prev.</source><year>2021</year><volume>30</volume><fpage>469</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-20-1319</pub-id><pub-id pub-id-type="pmid">33335023</pub-id><pub-id pub-id-type="pmcid">PMC7611188</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Carver, T. et al. CanRisk tool-A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. <italic toggle="yes">Cancer Epidemiol. Biomarkers Prev.</italic><bold>30</bold>, 469&#8211;473 (2021).<pub-id pub-id-type="pmid">33335023</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-20-1319</pub-id><pub-id pub-id-type="pmcid">PMC7611188</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>